WO2022213980A1 - Inhibiteur de tyk2 et son utilisation - Google Patents
Inhibiteur de tyk2 et son utilisation Download PDFInfo
- Publication number
- WO2022213980A1 WO2022213980A1 PCT/CN2022/085308 CN2022085308W WO2022213980A1 WO 2022213980 A1 WO2022213980 A1 WO 2022213980A1 CN 2022085308 W CN2022085308 W CN 2022085308W WO 2022213980 A1 WO2022213980 A1 WO 2022213980A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- methyl
- hydrogen
- methoxy
- mmol
- Prior art date
Links
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 272
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims abstract description 47
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 150000002148 esters Chemical class 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 230000001404 mediated effect Effects 0.000 claims abstract description 14
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims abstract 4
- 238000006243 chemical reaction Methods 0.000 claims description 204
- 238000002360 preparation method Methods 0.000 claims description 186
- -1 acid anhydride compounds Chemical class 0.000 claims description 154
- 125000000217 alkyl group Chemical group 0.000 claims description 145
- 229910052739 hydrogen Inorganic materials 0.000 claims description 116
- 239000001257 hydrogen Substances 0.000 claims description 113
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 94
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 83
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 80
- 150000002431 hydrogen Chemical class 0.000 claims description 77
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 72
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 67
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 64
- 125000003545 alkoxy group Chemical group 0.000 claims description 57
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 52
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 51
- 125000002947 alkylene group Chemical group 0.000 claims description 44
- 125000000623 heterocyclic group Chemical group 0.000 claims description 43
- 229910052736 halogen Inorganic materials 0.000 claims description 40
- 150000002367 halogens Chemical class 0.000 claims description 40
- 230000002829 reductive effect Effects 0.000 claims description 40
- 229910052799 carbon Inorganic materials 0.000 claims description 36
- 239000000543 intermediate Substances 0.000 claims description 36
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 31
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 29
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical group [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 26
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 25
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 21
- 125000004076 pyridyl group Chemical group 0.000 claims description 21
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 claims description 20
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 19
- 125000004429 atom Chemical group 0.000 claims description 19
- 230000000155 isotopic effect Effects 0.000 claims description 19
- 239000003054 catalyst Substances 0.000 claims description 18
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 18
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- 201000004681 Psoriasis Diseases 0.000 claims description 14
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 13
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 13
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 claims description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 11
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 8
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 8
- 125000002883 imidazolyl group Chemical group 0.000 claims description 8
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 229910052763 palladium Inorganic materials 0.000 claims description 7
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 6
- 239000004305 biphenyl Substances 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 claims description 6
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 claims description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical group CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 claims description 5
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 4
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 4
- 201000005569 Gout Diseases 0.000 claims description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 4
- SACNIGZYDTUHKB-UHFFFAOYSA-N ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C SACNIGZYDTUHKB-UHFFFAOYSA-N 0.000 claims description 4
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000003495 polar organic solvent Substances 0.000 claims description 4
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 claims description 3
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 claims description 3
- 150000007530 organic bases Chemical group 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- UNEATYXSUBPPKP-UHFFFAOYSA-N 1,3-Diisopropylbenzene Chemical compound CC(C)C1=CC=CC(C(C)C)=C1 UNEATYXSUBPPKP-UHFFFAOYSA-N 0.000 claims description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 2
- ZEMZPXWZVTUONV-UHFFFAOYSA-N 2-(2-dicyclohexylphosphanylphenyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 ZEMZPXWZVTUONV-UHFFFAOYSA-N 0.000 claims description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 2
- GKMIQVRCOHHFCD-UHFFFAOYSA-N 2-bromobutane;magnesium Chemical compound [Mg].CCC(C)Br GKMIQVRCOHHFCD-UHFFFAOYSA-N 0.000 claims description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 claims description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 2
- PWRBCZZQRRPXAB-UHFFFAOYSA-N 3-chloropyridine Chemical compound ClC1=CC=CN=C1 PWRBCZZQRRPXAB-UHFFFAOYSA-N 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 239000012388 BrettPhos 3rd generation precatalyst Substances 0.000 claims description 2
- NJTZSWLQBQJUHK-UHFFFAOYSA-N CCCP(=O)=O Chemical compound CCCP(=O)=O NJTZSWLQBQJUHK-UHFFFAOYSA-N 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 239000007821 HATU Substances 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000007868 Raney catalyst Substances 0.000 claims description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 2
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 239000012317 TBTU Substances 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000003308 autosomal dominant familial periodic fever Diseases 0.000 claims description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- WYXUZTXCGKPAEH-UHFFFAOYSA-N bromoethane;magnesium Chemical compound [Mg].CCBr WYXUZTXCGKPAEH-UHFFFAOYSA-N 0.000 claims description 2
- MKJQIOMCOYQKNP-UHFFFAOYSA-N bromomethane;magnesium Chemical compound [Mg].BrC MKJQIOMCOYQKNP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001718 carbodiimides Chemical class 0.000 claims description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 2
- 239000013522 chelant Substances 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- 239000007822 coupling agent Substances 0.000 claims description 2
- 239000012024 dehydrating agents Substances 0.000 claims description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 claims description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 claims description 2
- WDVGNXKCFBOKDF-UHFFFAOYSA-N dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 WDVGNXKCFBOKDF-UHFFFAOYSA-N 0.000 claims description 2
- REWLCYPYZCHYSS-UHFFFAOYSA-N ditert-butyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C(C)(C)C)C(C)(C)C REWLCYPYZCHYSS-UHFFFAOYSA-N 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 229910000462 iron(III) oxide hydroxide Inorganic materials 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 208000025487 periodic fever syndrome Diseases 0.000 claims description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
- 125000005544 phthalimido group Chemical group 0.000 claims description 2
- 150000004032 porphyrins Chemical class 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 229910052979 sodium sulfide Inorganic materials 0.000 claims description 2
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 claims description 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- ZGNPLWZYVAFUNZ-UHFFFAOYSA-N tert-butylphosphane Chemical compound CC(C)(C)P ZGNPLWZYVAFUNZ-UHFFFAOYSA-N 0.000 claims 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims 1
- RILZRCJGXSFXNE-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenyl]ethanol Chemical compound OCCC1=CC=C(OC(F)(F)F)C=C1 RILZRCJGXSFXNE-UHFFFAOYSA-N 0.000 claims 1
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 claims 1
- TWBPWBPGNQWFSJ-UHFFFAOYSA-N 2-phenylaniline Chemical group NC1=CC=CC=C1C1=CC=CC=C1 TWBPWBPGNQWFSJ-UHFFFAOYSA-N 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N acetic acid;palladium Chemical compound [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 260
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 189
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 138
- 239000000243 solution Substances 0.000 description 125
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 94
- 239000011541 reaction mixture Substances 0.000 description 90
- 235000019439 ethyl acetate Nutrition 0.000 description 87
- 239000000203 mixture Substances 0.000 description 84
- 239000012043 crude product Substances 0.000 description 75
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 59
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 53
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 51
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 51
- 239000000741 silica gel Substances 0.000 description 51
- 229910002027 silica gel Inorganic materials 0.000 description 51
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 50
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 49
- 108010010057 TYK2 Kinase Proteins 0.000 description 48
- 239000012044 organic layer Substances 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 43
- 238000005481 NMR spectroscopy Methods 0.000 description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 39
- 239000003208 petroleum Substances 0.000 description 39
- 238000000746 purification Methods 0.000 description 36
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 34
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 31
- 238000003818 flash chromatography Methods 0.000 description 31
- 230000002401 inhibitory effect Effects 0.000 description 29
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 27
- 239000012267 brine Substances 0.000 description 26
- 239000000872 buffer Substances 0.000 description 26
- 239000012074 organic phase Substances 0.000 description 25
- 230000019491 signal transduction Effects 0.000 description 25
- 235000019270 ammonium chloride Nutrition 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 22
- 238000010791 quenching Methods 0.000 description 22
- 150000001721 carbon Chemical group 0.000 description 21
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- 125000001424 substituent group Chemical group 0.000 description 19
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 239000012091 fetal bovine serum Substances 0.000 description 17
- 239000012299 nitrogen atmosphere Substances 0.000 description 17
- KVLSUFLTCCJFAG-UHFFFAOYSA-N 4,6-dichloro-n-methylpyridazine-3-carboxamide Chemical compound CNC(=O)C1=NN=C(Cl)C=C1Cl KVLSUFLTCCJFAG-UHFFFAOYSA-N 0.000 description 16
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- 238000004440 column chromatography Methods 0.000 description 14
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 13
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 13
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 13
- 229910002092 carbon dioxide Inorganic materials 0.000 description 13
- 239000001569 carbon dioxide Substances 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 11
- 239000012312 sodium hydride Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 230000002441 reversible effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 9
- 102000013462 Interleukin-12 Human genes 0.000 description 9
- 108010065805 Interleukin-12 Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 8
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 8
- 102000042838 JAK family Human genes 0.000 description 8
- 108091082332 JAK family Proteins 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 229960002751 imiquimod Drugs 0.000 description 8
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000011259 mixed solution Substances 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 8
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 7
- 102000013264 Interleukin-23 Human genes 0.000 description 7
- 108010065637 Interleukin-23 Proteins 0.000 description 7
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 7
- 125000003367 polycyclic group Chemical group 0.000 description 7
- 238000004237 preparative chromatography Methods 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 6
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000012192 staining solution Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 5
- DMDAOQLUHOAYAP-UHFFFAOYSA-N 4,6-dichloro-n-methylpyridine-3-carboxamide Chemical compound CNC(=O)C1=CN=C(Cl)C=C1Cl DMDAOQLUHOAYAP-UHFFFAOYSA-N 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 5
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 5
- 102000015774 TYK2 Kinase Human genes 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- DMYLUKNFEYWGCH-UHFFFAOYSA-N pyridazine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=N1 DMYLUKNFEYWGCH-UHFFFAOYSA-N 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- KOCFWIQBPUMTKV-UHFFFAOYSA-N CCOC(CC(C=C1[N+]([O-])=O)=CC(Br)=C1OC)=O Chemical compound CCOC(CC(C=C1[N+]([O-])=O)=CC(Br)=C1OC)=O KOCFWIQBPUMTKV-UHFFFAOYSA-N 0.000 description 4
- MCOCBZYGFZZUMU-UHFFFAOYSA-N CN(C=C1)N=C1C(C=C(CCO)C=C1[N+]([O-])=O)=C1OC Chemical compound CN(C=C1)N=C1C(C=C(CCO)C=C1[N+]([O-])=O)=C1OC MCOCBZYGFZZUMU-UHFFFAOYSA-N 0.000 description 4
- 241000271317 Gonystylus bancanus Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000004262 preparative liquid chromatography Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 125000003003 spiro group Chemical group 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- ORSSSYCRPMAGHB-UHFFFAOYSA-N CC1=CN=C(C2=CC(CCOCC3=NC(N)=CC=C3)=CC(NC3=CC(Cl)=NC=C3C(NC)=O)=C2OC)N=C1 Chemical compound CC1=CN=C(C2=CC(CCOCC3=NC(N)=CC=C3)=CC(NC3=CC(Cl)=NC=C3C(NC)=O)=C2OC)N=C1 ORSSSYCRPMAGHB-UHFFFAOYSA-N 0.000 description 3
- TZNXYCNZCYUBRG-UHFFFAOYSA-N CCOC(CC(C=C1[N+]([O-])=O)=CC(C(N=C2)=NC=C2OC)=C1OC)=O Chemical compound CCOC(CC(C=C1[N+]([O-])=O)=CC(C(N=C2)=NC=C2OC)=C1OC)=O TZNXYCNZCYUBRG-UHFFFAOYSA-N 0.000 description 3
- WOXWTZGZUCIDGC-UHFFFAOYSA-N CN(C=C1)N=C1C(C=C(CCN)C=C1[N+]([O-])=O)=C1OC Chemical compound CN(C=C1)N=C1C(C=C(CCN)C=C1[N+]([O-])=O)=C1OC WOXWTZGZUCIDGC-UHFFFAOYSA-N 0.000 description 3
- YPMOYCYQSFXNQP-UHFFFAOYSA-N COC(C([N+]([O-])=O)=CC(CCO)=C1)=C1Br Chemical compound COC(C([N+]([O-])=O)=CC(CCO)=C1)=C1Br YPMOYCYQSFXNQP-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- 210000000068 Th17 cell Anatomy 0.000 description 3
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000000021 kinase assay Methods 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 125000000109 phenylethoxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])O* 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 238000004808 supercritical fluid chromatography Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- MSAVICSPFQKRGG-UHFFFAOYSA-N 2-(4-fluoro-3-nitrophenyl)ethanol Chemical compound OCCC1=CC=C(F)C([N+]([O-])=O)=C1 MSAVICSPFQKRGG-UHFFFAOYSA-N 0.000 description 2
- BQQFAVSSAHZFMA-UHFFFAOYSA-N 2-bromo-4-(2-hydroxyethyl)phenol Chemical compound OCCC1=CC=C(O)C(Br)=C1 BQQFAVSSAHZFMA-UHFFFAOYSA-N 0.000 description 2
- KVLSUFLTCCJFAG-FIBGUPNXSA-N 4,6-dichloro-n-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(=O)C1=NN=C(Cl)C=C1Cl KVLSUFLTCCJFAG-FIBGUPNXSA-N 0.000 description 2
- IPWLQQBKTBBLID-UHFFFAOYSA-N 4-(2-hydroxyethyl)-2-nitrophenol Chemical compound OCCC1=CC=C(O)C([N+]([O-])=O)=C1 IPWLQQBKTBBLID-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- GNGCSXRLPFHKIO-UHFFFAOYSA-N 6-[(2-methylpropan-2-yl)oxycarbonylamino]pyridine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(C(O)=O)=N1 GNGCSXRLPFHKIO-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- AEFDBDSXNBJEOK-UHFFFAOYSA-N CC(C)(C)OC(NC1=NC(COCCC(C=C2C(N=C3)=NC=C3OC)=CC(NC3=CC(Cl)=NC=C3C(NC)=O)=C2OC)=CC=C1)=O Chemical compound CC(C)(C)OC(NC1=NC(COCCC(C=C2C(N=C3)=NC=C3OC)=CC(NC3=CC(Cl)=NC=C3C(NC)=O)=C2OC)=CC=C1)=O AEFDBDSXNBJEOK-UHFFFAOYSA-N 0.000 description 2
- ARMYOUKQZCJWRB-UHFFFAOYSA-N CC(OCCC(C=C1[N+]([O-])=O)=CC(C(OC)=O)=C1O)=O Chemical compound CC(OCCC(C=C1[N+]([O-])=O)=CC(C(OC)=O)=C1O)=O ARMYOUKQZCJWRB-UHFFFAOYSA-N 0.000 description 2
- ACHLMBQOGHREII-UHFFFAOYSA-N CC(OCCC(C=C1[N+]([O-])=O)=CC(C(OC)=O)=C1OC)=O Chemical compound CC(OCCC(C=C1[N+]([O-])=O)=CC(C(OC)=O)=C1OC)=O ACHLMBQOGHREII-UHFFFAOYSA-N 0.000 description 2
- DJBSAGXWIXHMMF-UHFFFAOYSA-N CCOC(CC(C=C1C2=NC=CC=N2)=CC([N+]([O-])=O)=C1OC)=O Chemical compound CCOC(CC(C=C1C2=NC=CC=N2)=CC([N+]([O-])=O)=C1OC)=O DJBSAGXWIXHMMF-UHFFFAOYSA-N 0.000 description 2
- HNDXRPBQWCFSEL-UHFFFAOYSA-N CCOC(CC(C=C1[N+]([O-])=O)=CC(C2=CN(C)N=C2)=C1OC)=O Chemical compound CCOC(CC(C=C1[N+]([O-])=O)=CC(C2=CN(C)N=C2)=C1OC)=O HNDXRPBQWCFSEL-UHFFFAOYSA-N 0.000 description 2
- BGGVUEJRJGRIJY-UHFFFAOYSA-N CCOC(CC(C=C1[N+]([O-])=O)=CC(C2=NN(C)C=C2)=C1OC)=O Chemical compound CCOC(CC(C=C1[N+]([O-])=O)=CC(C2=NN(C)C=C2)=C1OC)=O BGGVUEJRJGRIJY-UHFFFAOYSA-N 0.000 description 2
- ZTKRSQNDCBSUGN-UHFFFAOYSA-N CN(C=C1)N=C1C(C=C(CCS)C=C1[N+]([O-])=O)=C1OC Chemical compound CN(C=C1)N=C1C(C=C(CCS)C=C1[N+]([O-])=O)=C1OC ZTKRSQNDCBSUGN-UHFFFAOYSA-N 0.000 description 2
- KABMPBVUPMLOBA-UHFFFAOYSA-N CN1N=C(C(C=C(CCOCC2=CC=CC(Br)=N2)C=C2[N+]([O-])=O)=C2OC)N=C1 Chemical compound CN1N=C(C(C=C(CCOCC2=CC=CC(Br)=N2)C=C2[N+]([O-])=O)=C2OC)N=C1 KABMPBVUPMLOBA-UHFFFAOYSA-N 0.000 description 2
- KRFXJAYVNZBVQM-UHFFFAOYSA-N CN1N=CC(C(C=C(CCO)C=C2[N+]([O-])=O)=C2OC)=C1 Chemical compound CN1N=CC(C(C=C(CCO)C=C2[N+]([O-])=O)=C2OC)=C1 KRFXJAYVNZBVQM-UHFFFAOYSA-N 0.000 description 2
- LFEKUVSQQDDHSJ-UHFFFAOYSA-N CNC(C(C(NC(C=C(CCOCC1=NC(N)=CC=C1)C=C1C(N=C2)=NC=C2OC)=C1OC)=C1)=CN=C1Cl)=O Chemical compound CNC(C(C(NC(C=C(CCOCC1=NC(N)=CC=C1)C=C1C(N=C2)=NC=C2OC)=C1OC)=C1)=CN=C1Cl)=O LFEKUVSQQDDHSJ-UHFFFAOYSA-N 0.000 description 2
- DHUYLYZZINROBR-UHFFFAOYSA-N CNCCC(C=C1[N+]([O-])=O)=CC(C2=NN(C)C=C2)=C1OC Chemical compound CNCCC(C=C1[N+]([O-])=O)=CC(C2=NN(C)C=C2)=C1OC DHUYLYZZINROBR-UHFFFAOYSA-N 0.000 description 2
- YHRDOFZGINRZAM-UHFFFAOYSA-N COC(C(C1=NNC=N1)=CC(CCO)=C1)=C1[N+]([O-])=O Chemical compound COC(C(C1=NNC=N1)=CC(CCO)=C1)=C1[N+]([O-])=O YHRDOFZGINRZAM-UHFFFAOYSA-N 0.000 description 2
- ZKPDCVCGIRBBKB-UHFFFAOYSA-N COC(C([N+]([O-])=O)=CC(CCO)=C1)=C1C(N)=O Chemical compound COC(C([N+]([O-])=O)=CC(CCO)=C1)=C1C(N)=O ZKPDCVCGIRBBKB-UHFFFAOYSA-N 0.000 description 2
- VAIGCPHSFJAYEH-UHFFFAOYSA-N COC1=CC=C(CCO)C=C1[N+]([O-])=O Chemical compound COC1=CC=C(CCO)C=C1[N+]([O-])=O VAIGCPHSFJAYEH-UHFFFAOYSA-N 0.000 description 2
- BVKJRWJTXFKESS-UHFFFAOYSA-N COC1=CN=C(C(C=C(CCO)C=C2[N+]([O-])=O)=C2OC)N=C1 Chemical compound COC1=CN=C(C(C=C(CCO)C=C2[N+]([O-])=O)=C2OC)N=C1 BVKJRWJTXFKESS-UHFFFAOYSA-N 0.000 description 2
- KSCGLKQGLTUTIG-UHFFFAOYSA-N COC1=CN=C(C(C=C(CCOCC2=NC(Br)=CC=C2)C=C2[N+]([O-])=O)=C2OC)N=C1 Chemical compound COC1=CN=C(C(C=C(CCOCC2=NC(Br)=CC=C2)C=C2[N+]([O-])=O)=C2OC)N=C1 KSCGLKQGLTUTIG-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 102000000887 Transcription factor STAT Human genes 0.000 description 2
- 108050007918 Transcription factor STAT Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- NMJJFJNHVMGPGM-UHFFFAOYSA-N butyl formate Chemical compound CCCCOC=O NMJJFJNHVMGPGM-UHFFFAOYSA-N 0.000 description 2
- 125000005518 carboxamido group Chemical group 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- GPAYUJZHTULNBE-UHFFFAOYSA-O diphenylphosphanium Chemical compound C=1C=CC=CC=1[PH2+]C1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-O 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- MGCHVOUGRUJITM-UHFFFAOYSA-N methyl 6-[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)=N1 MGCHVOUGRUJITM-UHFFFAOYSA-N 0.000 description 2
- ASNYRAXHXYEHDP-UHFFFAOYSA-N methyl 6-amino-3-methylpyridine-2-carboxylate Chemical compound COC(=O)C1=NC(N)=CC=C1C ASNYRAXHXYEHDP-UHFFFAOYSA-N 0.000 description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- ZXRNZPGQEIKABL-UHFFFAOYSA-N tert-butyl n-[6-(bromomethyl)pyridin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(CBr)=N1 ZXRNZPGQEIKABL-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- RYGOBSYXIIUFOR-UHFFFAOYSA-N (1-methylpyrazol-4-yl)boronic acid Chemical compound CN1C=C(B(O)O)C=N1 RYGOBSYXIIUFOR-UHFFFAOYSA-N 0.000 description 1
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- WWUQRUIBJJBKLS-UHFFFAOYSA-N (2-methylpropan-2-yl)oxycarbonylcarbamic acid Chemical compound CC(C)(C)OC(=O)NC(O)=O WWUQRUIBJJBKLS-UHFFFAOYSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- VSTXCZGEEVFJES-UHFFFAOYSA-N 1-cycloundecyl-1,5-diazacycloundec-5-ene Chemical compound C1CCCCCC(CCCC1)N1CCCCCC=NCCC1 VSTXCZGEEVFJES-UHFFFAOYSA-N 0.000 description 1
- XUPLLYWDRKEULX-UHFFFAOYSA-N 1-hydroxycyclohexa-2,4-diene-1-carboxylic acid;2h-triazole Chemical compound C1=CNN=N1.OC(=O)C1(O)CC=CC=C1 XUPLLYWDRKEULX-UHFFFAOYSA-N 0.000 description 1
- YYKBFGMYHQMXIL-UHFFFAOYSA-N 1-phenyl-2,3,4-tri(propan-2-yl)benzene Chemical group CC(C)C1=C(C(C)C)C(C(C)C)=CC=C1C1=CC=CC=C1 YYKBFGMYHQMXIL-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- DPZWHUYAABAFKP-UHFFFAOYSA-N 2-bromo-5-methoxypyrimidine Chemical compound COC1=CN=C(Br)N=C1 DPZWHUYAABAFKP-UHFFFAOYSA-N 0.000 description 1
- KYCGEJNZMHUBMX-UHFFFAOYSA-N 2-bromo-5-methylpyrimidine Chemical compound CC1=CN=C(Br)N=C1 KYCGEJNZMHUBMX-UHFFFAOYSA-N 0.000 description 1
- BYQJMBHZLIDFBY-UHFFFAOYSA-N 2-bromo-6-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC(Br)=N1 BYQJMBHZLIDFBY-UHFFFAOYSA-N 0.000 description 1
- UPSXAPQYNGXVBF-UHFFFAOYSA-N 2-bromobutane Chemical compound CCC(C)Br UPSXAPQYNGXVBF-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- XNDZQQSKSQTQQD-UHFFFAOYSA-N 3-methylcyclohex-2-en-1-ol Chemical compound CC1=CC(O)CCC1 XNDZQQSKSQTQQD-UHFFFAOYSA-N 0.000 description 1
- ILMIEWNDXAKVNI-UHFFFAOYSA-N 4,6-dichloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)C=C1Cl ILMIEWNDXAKVNI-UHFFFAOYSA-N 0.000 description 1
- FLCOFHGXMMGYDB-UHFFFAOYSA-N 4-fluoro-3-nitrophenylacetic acid Chemical compound OC(=O)CC1=CC=C(F)C([N+]([O-])=O)=C1 FLCOFHGXMMGYDB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- HDGPLLHLIYXECO-UHFFFAOYSA-N C(=O)O.C(N)(OC)=O Chemical compound C(=O)O.C(N)(OC)=O HDGPLLHLIYXECO-UHFFFAOYSA-N 0.000 description 1
- ONKRUKGOUJBEBZ-UHFFFAOYSA-N CC(C)(C)OC(NC1=NC(COCCC(C=C2)=CC([N+]([O-])=O)=C2SC)=CC=C1)=O Chemical compound CC(C)(C)OC(NC1=NC(COCCC(C=C2)=CC([N+]([O-])=O)=C2SC)=CC=C1)=O ONKRUKGOUJBEBZ-UHFFFAOYSA-N 0.000 description 1
- SIAZXUPBNWNKOG-UHFFFAOYSA-N CC(C)(C)OC(NC1=NC(COCCC(C=C2C(N=C3)=NC=C3OC)=CC(N)=C2OC)=CC=C1)=O Chemical compound CC(C)(C)OC(NC1=NC(COCCC(C=C2C(N=C3)=NC=C3OC)=CC(N)=C2OC)=CC=C1)=O SIAZXUPBNWNKOG-UHFFFAOYSA-N 0.000 description 1
- DPGWLDQCWQSGHK-UHFFFAOYSA-N CNC(C(C(NC(C=C(CCOCC1=NC(N)=CC=C1)C=C1C2=NN(C)C=N2)=C1OC)=C1)=CN=C1Cl)=O Chemical compound CNC(C(C(NC(C=C(CCOCC1=NC(N)=CC=C1)C=C1C2=NN(C)C=N2)=C1OC)=C1)=CN=C1Cl)=O DPGWLDQCWQSGHK-UHFFFAOYSA-N 0.000 description 1
- BYKILDDPJRGNKK-UHFFFAOYSA-N CNC(C(N=NC(Cl)=C1)=C1NC(C=C(CCNC(C1=NC(N)=CC=C1)=O)C=C1C2=NN(C)C=C2)=C1OC)=O Chemical compound CNC(C(N=NC(Cl)=C1)=C1NC(C=C(CCNC(C1=NC(N)=CC=C1)=O)C=C1C2=NN(C)C=C2)=C1OC)=O BYKILDDPJRGNKK-UHFFFAOYSA-N 0.000 description 1
- IXXCHPFUQPEJMT-UHFFFAOYSA-N COC(C(C1=NC=CC=N1)=CC(CCO)=C1)=C1[N+]([O-])=O Chemical compound COC(C(C1=NC=CC=N1)=CC(CCO)=C1)=C1[N+]([O-])=O IXXCHPFUQPEJMT-UHFFFAOYSA-N 0.000 description 1
- GDKUAQIUBUVAJF-UHFFFAOYSA-N CS(=O)(=O)O.C1(CCCCC1)P(C1=C(C=CC=C1)C1=C(C=CC=C1OC(C)C)OC(C)C)C1CCCCC1 Chemical group CS(=O)(=O)O.C1(CCCCC1)P(C1=C(C=CC=C1)C1=C(C=CC=C1OC(C)C)OC(C)C)C1CCCCC1 GDKUAQIUBUVAJF-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 101000652482 Homo sapiens TBC1 domain family member 8 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 description 1
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 1
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 1
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 1
- 101710195550 Interleukin-23 receptor Proteins 0.000 description 1
- 102000008986 Janus Human genes 0.000 description 1
- 108050000950 Janus Proteins 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- UXRZLDREKITWRO-UHFFFAOYSA-N P(c1ccccc1)c1ccccc1.CC1(C)c2ccccc2Oc2ccccc12 Chemical compound P(c1ccccc1)c1ccccc1.CC1(C)c2ccccc2Oc2ccccc12 UXRZLDREKITWRO-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 102100030302 TBC1 domain family member 8 Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- JFGMTHKALVMZBY-GKOSEXJESA-N [2H]C([2H])([2H])NC(C(C(NC(C=C(CCOCC1=CC=CC(NC(OC(C)(C)C)=O)=N1)C=C1C2=NN(C)C=N2)=C1OC)=C1)=CN=C1Cl)=O Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=C(CCOCC1=CC=CC(NC(OC(C)(C)C)=O)=N1)C=C1C2=NN(C)C=N2)=C1OC)=C1)=CN=C1Cl)=O JFGMTHKALVMZBY-GKOSEXJESA-N 0.000 description 1
- DPGWLDQCWQSGHK-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(C(NC(C=C(CCOCC1=NC(N)=CC=C1)C=C1C2=NN(C)C=N2)=C1OC)=C1)=CN=C1Cl)=O Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=C(CCOCC1=NC(N)=CC=C1)C=C1C2=NN(C)C=N2)=C1OC)=C1)=CN=C1Cl)=O DPGWLDQCWQSGHK-FIBGUPNXSA-N 0.000 description 1
- OSRNIKRJTLTYNJ-UHFFFAOYSA-N [6-(bromomethyl)pyridin-2-yl]carbamic acid Chemical compound OC(=O)NC1=CC=CC(CBr)=N1 OSRNIKRJTLTYNJ-UHFFFAOYSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- UHKPOGGUWJGGID-UHFFFAOYSA-N carbonic acid;cesium Chemical compound [Cs].OC(O)=O UHKPOGGUWJGGID-UHFFFAOYSA-N 0.000 description 1
- QNEFNFIKZWUAEQ-UHFFFAOYSA-N carbonic acid;potassium Chemical compound [K].OC(O)=O QNEFNFIKZWUAEQ-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- FEHLGOYZDFFMND-UHFFFAOYSA-N cyclopropane-1,1-dicarboxamide Chemical compound NC(=O)C1(C(N)=O)CC1 FEHLGOYZDFFMND-UHFFFAOYSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- JZBWUTVDIDNCMW-UHFFFAOYSA-L dipotassium;oxido sulfate Chemical compound [K+].[K+].[O-]OS([O-])(=O)=O JZBWUTVDIDNCMW-UHFFFAOYSA-L 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- NLHWCTNYFFIPJT-UHFFFAOYSA-N disodium bis(trimethylsilyl)azanide Chemical compound [Na+].[Na+].C[Si](C)(C)[N-][Si](C)(C)C.C[Si](C)(C)[N-][Si](C)(C)C NLHWCTNYFFIPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- BTJRKNUKPQBLAL-UHFFFAOYSA-N hydron;4-methylmorpholine;chloride Chemical compound Cl.CN1CCOCC1 BTJRKNUKPQBLAL-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- JYJVVHFRSFVEJM-UHFFFAOYSA-N iodosobenzene Chemical compound O=IC1=CC=CC=C1 JYJVVHFRSFVEJM-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- YJUKTIBOUBUOJH-UHFFFAOYSA-N methyl 6-amino-3-bromopyridine-2-carboxylate Chemical compound COC(=O)C1=NC(N)=CC=C1Br YJUKTIBOUBUOJH-UHFFFAOYSA-N 0.000 description 1
- OHIHEJTUXNQOPM-UHFFFAOYSA-N methyl 6-aminopyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(N)=N1 OHIHEJTUXNQOPM-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- XEVGBKYKRAHUNV-UHFFFAOYSA-N methyl n-pyridin-2-ylcarbamate Chemical compound COC(=O)NC1=CC=CC=N1 XEVGBKYKRAHUNV-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- FFOLNPHHJUGQBY-UHFFFAOYSA-N n-methylpyridazine-3-carboxamide Chemical compound CNC(=O)C1=CC=CN=N1 FFOLNPHHJUGQBY-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- HJKYXKSLRZKNSI-UHFFFAOYSA-I pentapotassium;hydrogen sulfate;oxido sulfate;sulfuric acid Chemical compound [K+].[K+].[K+].[K+].[K+].OS([O-])(=O)=O.[O-]S([O-])(=O)=O.OS(=O)(=O)O[O-].OS(=O)(=O)O[O-] HJKYXKSLRZKNSI-UHFFFAOYSA-I 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- LHDMBYWDIBGTAR-UHFFFAOYSA-N phenyl hypoiodite Chemical compound IOC1=CC=CC=C1 LHDMBYWDIBGTAR-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- HDMGAZBPFLDBCX-UHFFFAOYSA-M potassium;sulfooxy sulfate Chemical compound [K+].OS(=O)(=O)OOS([O-])(=O)=O HDMGAZBPFLDBCX-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- ZOFJBHYCGASUQK-UHFFFAOYSA-N sodium;trimethylsilylazanide Chemical compound [Na+].C[Si](C)(C)[NH-] ZOFJBHYCGASUQK-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- UIYOVVYZPVVUMJ-UHFFFAOYSA-N tert-butyl carbamoyl carbonate Chemical compound CC(C)(C)OC(=O)OC(N)=O UIYOVVYZPVVUMJ-UHFFFAOYSA-N 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- LXYVNUSGHHMEDG-UHFFFAOYSA-N tert-butyl n-[6-(chloromethyl)pyridin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(CCl)=N1 LXYVNUSGHHMEDG-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Definitions
- the invention belongs to the field of medicine, in particular to a macrocyclic TYK2 inhibitor compound, its pharmaceutically acceptable salt, its ester, its isomer, its isotopic label, its composition, use and treatment method.
- Janus kinase is a non-receptor tyrosine protein kinase that plays a pivotal role in many cytokine receptor-mediated signal transduction, and is involved in the proliferation, differentiation, Important physiological processes such as apoptosis, angiogenesis and immune regulation.
- JAKs family has 4 different subtypes in mammals, namely JAK1, JAK2, JAK3 and TYK2 (tyrosine kinase2).
- JAK1, JAK2 and TYK2 are expressed in various tissues and cells of the human body.
- JAK-3 is mainly expressed in various tissues and cells. in hematopoietic cells.
- the JAK-STAT (Janus kinase-signal transducer and activator of tanscription) signaling pathway is the most important pathway mediated by JAKs in vivo. This pathway consists of ligands (such as cytokines), transmembrane receptors, JAK kinases and transcription factors. STAT consists of four parts.
- JAK is a non-receptor tyrosine kinase that activates receptor-coupled JAKs when extracellular ligands including specific growth factors, growth hormones, chemokines, and cytokines bind to cytokine receptors on the surface , make it have tyrosine kinase activity and bind in pairs, the dimeric JAK can undergo spontaneous phosphorylation, bind to STAT protein, the activated STAT protein is detached from the receptor and forms a phosphorylated dimer, which is transferred to the nucleus It binds to specific DNA sequences to exert physiological functions and regulate the transcription of target genes.
- Type I and II cytokines bind their receptors to subsequent intracellular signaling through the JAK kinase and signal transducer and activator of transcription (JAK–STAT) pathway.
- TYK2 mainly mediates the functions of cytokines such as IFN- ⁇ , IL-6, IL-10, IL-12 and IL-23.
- cytokines such as IFN- ⁇ , IL-6, IL-10, IL-12 and IL-23.
- TYK2-deficient mice are resistant to collagen-induced arthritis, colitis, psoriasis, and experimental allergic encephalomyelitis, suggesting that TYK2-mediated signaling plays a role in autoimmune and inflammation-related diseases. important role.
- Genome-wide association studies show that TYK2 variants are associated with autoimmune disorders such as Crohn's disease, psoriasis, systemic lupus erythematosus and rheumatoid arthritis, further demonstrating the importance of TYK2 in autoimmune and inflammation-related diseases .
- TYK2 selective inhibitors can inhibit the signal transduction cascade of IL-12, IL-23 and type I interferon receptors, including systemic lupus erythematosus, inflammatory bowel disease, psoriasis, A variety of autoimmune and inflammation-related animal models, including rheumatoid arthritis, play a therapeutic role, and a TYK2 selective inhibitor is currently undergoing II or III for systemic lupus erythematosus, Crohn's disease and psoriasis indications Phase clinical research, no TYK2 selective inhibitor has been listed.
- the problem to be solved by the present invention is to provide a macrocyclic compound with a good inhibitory effect on the TYK2 signaling pathway and a novel structure.
- the compound specifically targets the TYK2 regulatory protein domain (pseudokinase) and has an inhibitory effect on the TYK2 pathway.
- TYK2 regulatory protein domain pseudokinase
- JAK1, JAK2 and/or JAK3 signaling pathway it has stronger selectivity; further, the present invention provides a TYK2 inhibitor with high selectivity, good bioavailability, good efficacy and low toxicity class compounds.
- the present invention provides a compound represented by the following general formula (II'),
- X is selected from CH, N;
- R 1 is selected from hydrogen, C 1-6 alkyl, deuterated C 1-6 alkyl, cycloalkyl;
- R 8 is selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy
- R 1 is connected to R 8 , and forms a heterocycle together with the nitrogen atom to which it is connected;
- X 1 and X 2 are independently selected from CH 2 , NH, and O;
- Ring C is selected from aryl, heteroaryl, cycloalkyl, heterocyclyl;
- R is independently selected from R 2 or R 3 ;
- n is selected from 0, 1, 2, 3;
- R 2 is selected from hydrogen, -OH, C 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, deuterated C 1-6 alkoxy, C 1-6 alkyl- C(O)-, C 1-6 alkyl-S-, C 1-6 alkyl-S(O)-, C 1-6 alkyl-S(O) 2- ;
- R 3 is selected from hydrogen, C 1-6 alkoxy-C(O)-, (R 5 )(R 6 )NC(O)-, or the following groups optionally substituted with one or more Ra : Phenyl, heteroaryl, heterocyclyl, cycloalkyl;
- R a is selected from hydrogen, halogen, -CN, carboxyl, (R 5 )(R 6 )NC(O)-, C 1-6 alkyl, C 1-6 alkyl-C(O)-, C 1- 6 alkyl-C(O)-NH-, halogenated C 1-6 alkyl, halogenated C 1-6 alkoxy, hydroxy C 1-6 alkyl, C 1-6 alkoxy, cycloalkyl , cycloalkyl-(CH 2 )pO-, NC-cycloalkyl, or any two adjacent R a are connected to form a heterocycle together with the atoms to which they are connected; p is selected from 0, 1, 2, 3;
- L 1 is selected from C 1-8 alkylene optionally substituted by one or more R b , and one or more CH 2 in said C 1-8 alkylene is optionally substituted by -C(O)-, -NR 7 -, -S, -S(O)-, -S(O) 2- and/or -O-substituted;
- R b is selected from C 1-6 alkyl, or two R b located on the same carbon atom and the carbon atom to which it is attached together form cycloalkyl, heterocyclyl;
- L 1 is selected from Wherein the ring A end is connected with the X of formula ( II '), and the L end is connected with the ring C;
- Ring A is selected from aryl, heteroaryl
- L 2 is selected from C 1-6 alkylene optionally substituted by one or more R c , and one or more CH 2 in said C 1-6 alkylene is optionally substituted by -C(O)-, -NR 7 -, -S-, -S(O)-, -S(O) 2 - and/or -O-substituted;
- R c is selected from C 1-6 alkyl, or both are located on the same carbon atom R c and its attached carbon atoms together form cycloalkyl, heterocyclyl;
- R 4 is selected from hydrogen, halogen, C 1-6 alkyl, halogenated C 1-6 alkyl, phenyl, cycloalkyl, and the phenyl is optionally composed of one or more selected from halogen, C 1-6 6 alkyl, C 1-6 alkoxy or halogenated C 1-6 alkyl group substituted;
- n 0, 1, 2, 3;
- R 5 and R 6 are independently selected from hydrogen, -OH, C 1-6 alkyl, cycloalkyl, or R 5 and R 6 are connected together, and together with the nitrogen atom to which they are connected, form a heterocycle;
- R 7 is selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyl-C(O)-, -C(O)OCH 2 Ph.
- X is selected from CH, N;
- R 1 is selected from hydrogen, C 1-6 alkyl, deuterated C 1-6 alkyl, cycloalkyl;
- R 8 is selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy
- R 1 is connected with R 8 to form a 3-8 membered heterocycle together with the nitrogen atom to which it is connected;
- R 2 is selected from hydrogen, -OH, C 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, deuterated C 1-6 alkoxy, C 1-6 alkyl- C(O)-, C 1-6 alkyl-S-, C 1-6 alkyl-S(O)-, C 1-6 alkyl-S(O) 2- ;
- R 3 is selected from hydrogen, C 1-6 alkoxy-C(O)-, (R 5 )(R 6 )NC(O)-, or the following groups optionally substituted with one or more Ra : Phenyl, heteroaryl, heterocyclyl, cycloalkyl;
- R a is selected from hydrogen, halogen, -CN, carboxyl, (R 5 )(R 6 )NC(O)-, C 1-6 alkyl, C 1-6 alkyl-C(O)-, C 1- 6 alkyl-C(O)-NH-, halogenated C 1-6 alkyl, halogenated C 1-6 alkoxy, hydroxy C 1-6 alkyl, C 1-6 alkoxy, 3-8 membered cycloalkyl, 3-8 membered cycloalkyl-O-, 3-8 membered cycloalkyl-C 1-6 alkoxy, NC-3-8 membered cycloalkyl, or any two adjacent R a Connected to and together form a 3-8 membered heterocycle with the atoms to which it is connected;
- p is selected from 0, 1, 2, 3;
- L 1 is selected from C 1-8 alkylene optionally substituted by one or more R b , and one or more CH 2 in said C 1-8 alkylene is optionally substituted by -C(O)-, -NR 7 -, -S, -S(O)-, -S(O) 2- and/or -O-substituted;
- R b is selected from C 1-4 alkyl, or two carbon atoms located on the same carbon atom. R b together with the carbon atom to which it is attached forms a 3-5 membered cycloalkyl;
- L 1 is selected from Wherein the ring A end is connected with the NH of formula (I'), and the L 2 end is connected with the benzene ring;
- Ring A is selected from phenyl, heteroaryl
- L 2 is selected from C 1-6 alkylene optionally substituted by one or more R c , and one or more CH 2 in said C 1-6 alkylene is optionally substituted by -C(O)-, -NR 7 -, -S-, -S(O)-, -S(O) 2 - and/or -O-substituted;
- R c is selected from C 1-6 alkyl, or both are located on the same carbon atom The R c and the carbon atom to which it is attached together form a 3-8 membered cycloalkyl;
- R 4 is selected from hydrogen, halogen, C 1-6 alkyl, halogenated C 1-6 alkyl, phenyl, 3-8 membered cycloalkyl, and the phenyl is optionally selected from one or more halogens , C 1-6 alkyl, C 1-6 alkoxy or halogenated C 1-6 alkyl group substitution;
- n 0, 1, 2, 3;
- R 5 , R 6 are independently selected from hydrogen, -OH, C 1-6 alkyl, 3-8 membered cycloalkyl, or R 5 and R 6 are connected together, and together with the nitrogen atom to which they are connected, form a 3-8 membered Heterocycle;
- R 7 is selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyl-C(O)-, -C(O)OCH 2 Ph.
- X is selected from CH, N;
- R 1 is selected from hydrogen, C 1-6 alkyl, deuterated C 1-6 alkyl, cycloalkyl;
- R 2 is selected from hydrogen, -OH, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyl-C(O)-, C 1-6 alkyl-S-, C 1- 6 alkyl-S(O)-, C 1-6 alkyl-S(O) 2 -;
- R 3 is selected from hydrogen, C 1-6 alkoxy-C(O)-, (R 5 )(R 6 )NC(O)-, or the following groups optionally substituted with one or more Ra : Phenyl, heteroaryl;
- R a is selected from hydrogen, halogen, (R 5 )(R 6 )NC(O)-, C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkoxy;
- L 1 is selected from C 1-8 alkylene optionally substituted by one or more R b , and one or more CH 2 in said C 1-8 alkylene is optionally substituted by -C(O)-, -NR 7 -, -S, -S(O)-, -S(O) 2- and/or -O-substituted;
- R b is selected from C 1-4 alkyl, or two R b located on the same carbon atom together with the carbon atom to which it is attached form a 3-5 membered cycloalkyl;
- L 1 is selected from Wherein the ring A end is connected with the NH of formula (I'), and the L 2 end is connected with the benzene ring;
- Ring A is selected from phenyl, heteroaryl
- L 2 is selected from C 1-6 alkylene optionally substituted by one or more R c , and one or more CH 2 in said C 1-6 alkylene is optionally substituted by -C(O)-, -NR 7 -, -S-, -S(O)-, -S(O) 2 - and/or -O- substituted;
- R c is selected from C 1-6 alkyl, or two R c located on the same carbon atom together with the carbon atom to which it is attached form a 3-8 membered cycloalkyl;
- R 4 is selected from hydrogen, halogen, C 1-6 alkyl, halogenated C 1-6 alkyl, phenyl, 3-8 membered cycloalkyl, and the phenyl is optionally selected from one or more halogens , C 1-6 alkyl, C 1-6 alkoxy or halogenated C 1-6 alkyl group;
- n 0, 1, 2, 3;
- R 5 and R 6 are independently selected from hydrogen and C 1-6 alkyl
- R 7 is selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyl-C(O)-, -C(O)OCH 2 Ph;
- R 8 is selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy.
- X is selected from CH, N;
- R 1 is selected from hydrogen, C 1-4 alkyl, deuterated C 1-4 alkyl, 3-6 membered cycloalkyl;
- R 2 is selected from hydrogen, -OH, C 1-4 alkyl, deuterated C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkyl-C(O)-, C 1-4 alkyl-S-, C 1-4 alkyl-S(O)-, C 1-4 alkyl-S(O) 2- ;
- R 3 is selected from hydrogen, C 1-4 alkoxy-C(O)-, (R 5 )(R 6 )NC(O)-, or the following groups optionally substituted with one or more Ra : Phenyl, 5-6 membered heteroaryl, 5-6 membered heterocyclyl;
- R a is selected from hydrogen, halogen, -CN, carboxyl, (R 5 )(R 6 )NC(O)-, C 1-4 alkyl, C 1-4 alkyl-C(O)-, C 1- 4 alkyl-C(O)-NH-, C 1-4 alkoxy, halogenated C 1-4 alkyl, halogenated C 1-4 alkoxy, hydroxy C 1-4 alkyl, 3-6 membered cycloalkyl, 3-6 membered cycloalkyl-O-, 3-6 membered cycloalkyl-C 1-4 alkoxy, NC-3-6 membered cycloalkyl, or any two adjacent R a Connected to and together form a 3-6 membered heterocycle with the atoms to which it is connected;
- L 1 is selected from C 1-8 alkylene optionally substituted by one or more R b , and one or more CH 2 in said C 1-8 alkylene is optionally substituted by -C(O)-, -NR 7 -, -S, -S(O)-, -S(O) 2- and/or -O-substituted;
- R b is selected from C 1-4 alkyl, or two R b located on the same carbon atom together with the carbon atom to which it is attached form a 3-5 membered cycloalkyl;
- L 1 is selected from Wherein the ring A end is connected with the NH end of formula (I), and the L 2 end is connected with the benzene ring;
- Ring A is selected from phenyl, 5-6 heteroaryl, or 8-10 membered fused ring heteroaryl;
- L 2 is selected from C 1-6 alkylene, and one or more CH 2 in said C 1-6 alkylene is optionally replaced by -C(O)-, -NR 7 -, -S-, -S (O)-, -S(O) 2 - and/or -O- substitution;
- R 4 is selected from hydrogen, halogen, C 1-4 alkyl, halogenated C 1-4 alkyl, phenyl, 3-6 membered cycloalkyl, the phenyl is optionally by one or more selected from halogen , C 1-4 alkyl, or halogenated C 1-4 alkyl group substitution;
- n 0, 1, 2, 3;
- R 5 and R 6 are independently selected from hydrogen, C 1-4 alkyl, 3-6-membered cycloalkyl, or R 5 and R 6 are connected together, and together with the nitrogen atom to which they are connected, form a 3-6-membered heterocycle;
- R 7 is selected from hydrogen, C 1-4 alkyl, C 1-4 alkyl-C(O)-, -C(O)OCH 2 Ph.
- X is selected from CH, N;
- R 1 is selected from hydrogen, C 1-4 alkyl, deuterated C 1-4 alkyl, 3-6 membered cycloalkyl;
- R 2 is selected from hydrogen, -OH, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkyl-C(O)-, C 1-4 alkyl-S-, C 1- 4 alkyl-S(O)-, C 1-4 alkyl-S(O) 2 -;
- R 3 is selected from hydrogen, C 1-4 alkoxy-C(O)-, (R 5 )(R 6 )NC(O)-, or the following groups optionally substituted with one or more Ra : Phenyl, 5-6 membered heteroaryl;
- R a is selected from hydrogen, halogen, (R 5 )(R 6 )NC(O)-, C 1-4 alkyl, C 1-4 alkoxy, halogenated C 1-4 alkyl;
- L 1 is selected from C 1-8 alkylene optionally substituted by one or more R b , and one or more CH 2 in said C 1-8 alkylene is optionally substituted by -C(O)-, -NR 7- , -S, -S(O)-, -S(O) 2 - and/or -O- substituted;
- R b is selected from C 1-4 alkyl, or two R b located on the same carbon atom together with the carbon atom to which it is attached form a 3-5 membered cycloalkyl;
- L 1 is selected from Wherein the ring A end is connected with the NH end of formula (I), and the L 2 end is connected with the benzene ring;
- Ring A is selected from phenyl, 5-6 heteroaryl, or 8-10 membered fused ring heteroaryl;
- L 2 is selected from C 1-6 alkylene, one or more CH 2 in said C 1-6 alkylene is optionally replaced by -C(O)-, -NR 7- , -S-, -S (O)-, -S(O) 2 - and/or -O- substitution;
- R 4 is selected from hydrogen, halogen, C 1-4 alkyl, halogenated C 1-4 alkyl, phenyl, 3-6 membered cycloalkyl, the phenyl is optionally by one or more selected from halogen , C 1-4 alkyl, or halogenated C 1-4 alkyl group;
- n 0, 1, 2, 3;
- R 5 and R 6 are independently selected from hydrogen and C 1-4 alkyl
- R 7 is selected from hydrogen, C 1-4 alkyl, C 1-4 alkyl-C(O)-, -C(O)OCH 2 Ph.
- R 1 is selected from H, -CH 3 , -CH 2 CH 3 , -CD 3 ,
- R 1 is selected from H, -CH 3 , -CH 2 CH 3 , -CD 3 ,
- R is selected from H
- R 1 is attached to R 8 to form together with the nitrogen atom to which it is attached
- R 3 is selected from hydrogen, -C(O)-OCH 3 , -C(O)-NH 2 , -C(O)-N(CH 3 ) 2 , or the following groups optionally substituted with 1-2 R a : pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, 1,2, 4-triazolyl, tetrazolyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl,
- Ra is selected from H, F, -CN, -COOH , -CH3 , -CH2CH3 , -CH2F , -CHF2 , -CF3 , -OCH3 , -OCH2CH3 , -O- CH(CH 3 ) 2 , -CF 2 CH 3 , -C(O)CH 3 , -OCHF 2 , -C(O)-N(CH 3 ) 2 , -C(O)-NHCH 3 , -NHC( O)CH 3 , -C(O)-NH 2 , Or two adjacent R a are connected and the atoms to which they are connected together form tetrahydrofuran and tetrahydropyrrole.
- R 3 is selected from hydrogen, -C(O)-OCH 3 , -C(O)-NH 2 , -C(O)-N( CH3 ) 2 , or selected from the following groups optionally substituted with 1-2 R a : pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, 1, 2,4-triazolyl, tetrazolyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl; R a is selected from hydrogen, F, -CH 3 , -CH 2 CH 3 , - CH 2 F, -CHF 2 , -CF 3 , -OCH 3 , -C(O)-N(CH 3 ) 2 .
- R 3 is selected from hydrogen, -C(O)-OCH 3 , -C(O)-NH 2 , Or selected from the following groups optionally substituted by 1-2 R a : pyrazolyl, imidazolyl, 1,2,4-triazolyl, phenyl, pyridyl, pyrimidinyl; R a is selected from hydrogen, F, -CH 3 , -CH 2 CH 3 , -OCH 3 .
- Ra is selected from hydrogen, F, -CH3 , -OCH3 , -O-CH( CH3 ) 2 .
- R 3 is selected from the following groups:
- R 3 is selected from the following groups:
- R is selected from
- L 1 is selected from “a” indicates that it is attached to X2 or NH through this end.
- R 4 is selected from hydrogen, fluorine, -CH 3 , -CF 3 ,
- n is selected from 0, 1 or 2.
- Ring A is selected from phenyl, pyridyl, pyrazolyl, imidazolyl, thiazolyl,
- ring A is selected from “a” indicates that it is attached to X2 or NH through this end.
- R7 is selected from hydrogen, -CH3 , -CH2CH3, -C(O) CH3 , -C (O ) OCH2Ph .
- L 2 is q 1 and q 2 are independently 0, 1, 2, 3, and 4;
- Y is -O-, -S-, -NR 7 -, -NR 7 -C(O)-, -C(R 7 ) 2 -, -OC(O)-, -S(O)-, -S(O) 2 -;
- R 7 is selected from hydrogen, C 1-4 alkyl, C 1-4 alkyl-C(O)- , -C(O)OCH 2 Ph, preferably, R 7 is selected from hydrogen, C 1-4 alkyl.
- L 2 is q 1 and q 2 are independently 0, 1, 2, 3, and 4;
- Y is -O-, -S-, -NR 7 -, -NR 7 -C(O)-, -C(R 7 ) 2 -, -OC(O)-, -S(O)-, -S(O) 2 -;
- R 7 is selected from hydrogen, -CH 3 , -CH 2 CH 3 , -C(O)CH 3 , - C(O) OCH2Ph .
- L 2 is q 1 and q 2 are independently 0, 1, 2, 3, and 4;
- Y is -O-, -S-, -NR 7 -, -NR 7 -C(O)-, -C(R 7 ) 2 -, -OC(O)-, -S(O)-, -S(O) 2 -;
- R 7 is selected from hydrogen, -CH 3 , -C(O)OCH 2 Ph.
- formula (II'), formula (I') or formula (I) the sum of q 1 and q 2 is 2-5; preferably 3 or 4.
- formula (II'), formula (I') or formula (I) the present invention further provides the compound represented by the following general formula, its pharmaceutically acceptable salt, its ester, its isomer , its isotopic label:
- R 1 , R 2 , R 3 , R a , R 4 , L 2 , ring A, m can be selected from the definitions of any scheme of the present invention.
- the compound of the present invention or its pharmaceutically acceptable salt, its ester, its isomer, its isotopic label, selected from the following compounds:
- a pharmaceutical preparation composition comprising the compound described in any one of the first aspect of the present invention, a pharmaceutically acceptable salt thereof, an ester thereof, an isomer thereof, an isotope thereof marker, and one or more pharmaceutically acceptable excipients.
- the pharmaceutical formulation can be any pharmaceutically acceptable dosage form.
- a pharmaceutically acceptable excipient is a substance that is non-toxic, compatible with the active ingredient and otherwise biologically suitable for the organism.
- the choice of a particular excipient will depend on the mode of administration or disease type and state used to treat the particular patient.
- pharmaceutically acceptable excipients include, but are not limited to, solvents, diluents, dispersants, suspending agents, surfactants, isotonic agents, thickeners, emulsifiers, binders, Lubricants, stabilizers, hydrating agents, emulsification accelerators, buffers, absorbents, colorants, ion exchangers, mold release agents, coating agents, flavoring agents, antioxidants, etc.
- flavoring agents, preservatives, sweetening agents, etc. can also be added to the pharmaceutical preparation composition.
- the above-described pharmaceutical formulation compositions may be administered orally, parenterally, rectally, or via pulmonary administration to a patient or subject in need of such treatment.
- the pharmaceutical composition can be made into oral preparations, for example, can be made into conventional oral solid preparations, such as tablets, capsules, pills, granules, etc.; can also be made into oral liquid preparations, such as Oral solution, oral suspension, syrup, etc.
- suitable fillers, binders, disintegrants, lubricants and the like can be added.
- parenteral administration the above-mentioned pharmaceutical preparations can also be prepared into injections, including injection solutions, sterile powders for injection and concentrated solutions for injection.
- the pharmaceutical composition When preparing the injection, it can be produced by the conventional methods in the existing pharmaceutical field. When preparing the injection, no additives can be added, or suitable additives can be added according to the properties of the drug.
- the pharmaceutical composition For rectal administration, the pharmaceutical composition can be formulated into suppositories and the like.
- the pharmaceutical composition For pulmonary administration, can be formulated into inhalation formulations, aerosol formulations, powder aerosol formulations or spray formulations, and the like.
- a pharmaceutical composition comprising the compound described in any one of the first aspect of the present invention, a pharmaceutically acceptable salt thereof, an ester thereof, an isomer thereof, an isotopic label thereof and one or more second therapeutically active agents
- the second therapeutically active agents can be selected from immunosuppressants, such as hormonal drugs, such as corticosteroids; from cytokine inhibitors; from kinase inhibitors ; selected from nuclear translocation inhibitors; selected from non-steroidal anti-inflammatory drugs, such as ibuprofen; selected from antiviral agents, such as abacavir; selected from anti-proliferative agents; selected from antimalarial drugs; selected from TNF - alpha inhibitors, etc.
- immunosuppressants such as hormonal drugs, such as corticosteroids
- cytokine inhibitors such as corticosteroids
- kinase inhibitors selected from nuclear translocation inhibitors
- non-steroidal anti-inflammatory drugs such as ibuprofen
- selected from antiviral agents
- the medicine is used to prevent and/or treat the related diseases mediated by TYK2 in patients or subjects; preferably, the related diseases mediated by TYK2 include autoimmune diseases, transplant-related diseases, inflammation Sexual or inflammatory disease.
- the TYK2-mediated related disease is mediated by the IL-12, IL-23 and/or IFN ⁇ signaling pathway.
- the autoimmune disease is selected from the group consisting of type 1 diabetes, Gray's disease, rheumatoid arthritis, ankylosing spondylitis, cutaneous lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, lupus Nephritis, multiple sclerosis, systemic sclerosis, Sjögren's syndrome, psoriasis, Crohn's disease, ulcerative colitis, and inflammatory bowel disease.
- the inflammatory or inflammatory disease is selected from the group consisting of rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, psoriasis, Crohn's disease, ulcerative colitis and inflammatory bowel disease, Cold porphyrin-associated periodic syndrome (CAPS), tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS), familial Mediterranean fever (FMF), adult Still's disease, systemic juvenile idiopathic arthritis, gout , gouty arthritis, osteoarthritis.
- CCAPS Cold porphyrin-associated periodic syndrome
- TRAPS tumor necrosis factor receptor-associated periodic fever syndrome
- FMF familial Mediterranean fever
- adult Still's disease systemic juvenile idiopathic arthritis, gout , gouty arthritis, osteoarthritis.
- the present invention also provides a method for treating related diseases mediated by TYK2, comprising administering to a patient or subject an effective amount of the compound described in any one of the first aspects of the present invention, Its pharmaceutically acceptable salts, its esters, its isomers, its isotopic labels.
- the present invention also provides a method of treating a related disease mediated by IL-12, IL-23 and/or IFN ⁇ , comprising administering to a patient or subject an effective amount of the first of the present invention
- a pharmaceutically acceptable salt thereof, an ester thereof, an isomer thereof, an isotopic label thereof comprising administering to a patient or subject an effective amount of the first of the present invention
- the present invention also provides a method of treating an autoimmune disease, comprising administering to a patient or subject an effective amount of the compound described in any one of the first aspects of the present invention, or a pharmaceutically acceptable compound thereof. Accepted salts, esters thereof, isomers thereof, isotopic labels thereof.
- the present invention provides a compound according to any one of the first aspects, a pharmaceutically acceptable salt thereof, an ester thereof, an isomer thereof, an isotopic label thereof, which can be used for the treatment of TYK2-mediated related diseases.
- pharmaceutically acceptable means, within the scope of sound medical judgment, suitable for use in contact with human and animal tissues without undue toxicity, irritation, allergic reaction or other problems or complications, with a reasonable benefit/risk ratio equivalent to those compounds, materials, compositions and/or dosage forms.
- the "pharmaceutically acceptable salt” in the present invention refers to a salt formed by an acidic functional group (such as -COOH, -OH, -SO 3 H, etc.) existing in a compound and an appropriate inorganic or organic cation (base), including Salts formed with alkali metals or alkaline earth metals, ammonium salts, and salts with nitrogen-containing organic bases; and salts with appropriate inorganic or organic anions (acids) of basic functional groups (such as -NH 2 , etc.) present in the compounds , including salts formed with inorganic or organic acids (eg, carboxylic acids, etc.).
- an acidic functional group such as -COOH, -OH, -SO 3 H, etc.
- base an appropriate inorganic or organic cation
- ester in the present invention refers to the product formed by the dehydration of acid and alcohol; when there is a -COOH group in the structure of the compound of the present invention, it can be dehydrated with a pharmaceutically acceptable alcohol compound to form an ester; when the present invention There is -OH in the compound structure, which can be dehydrated with pharmaceutically acceptable organic or inorganic acid compounds to form esters.
- the ester compound can produce the active compound of the present invention by means of metabolism or hydrolysis in vivo, and the ester can have biological activity similar to the free body or no or weak biological activity in vitro.
- the “isomers” in the present invention include geometric isomers as well as stereoisomers, such as cis-trans isomers, enantiomers, diastereomers, tautomers, and external isomers thereof. Racemic and other mixtures, all of which are within the scope of this invention.
- the term “enantiomers” refers to stereoisomers that are mirror images of each other.
- the term “tautomer” refers to a type of functional group isomer that has a different point of attachment of the hydrogen by displacement of one or more double bonds, for example, ketone and its enol form are keto-enol Tautomers.
- diastereomer refers to a stereoisomer in which a molecule has two or more chiral centers and the molecules are in a non-mirror-image relationship.
- cis-trans isomers refers to different spatial configurations in which double bonds or single bonds of ring carbon atoms cannot rotate freely in the molecule.
- terapéuticaally effective amount refers to an amount sufficient to produce a beneficial or desired effect when administered to a subject of a compound or composition or dosage form of the present invention; the effect may be the prevention of autoimmune symptoms Produce, and/or inhibit, reduce the development, spread of autoimmune symptoms, and/or improve clinical symptoms or indicators associated with autoimmune disease. It will be recognized, however, that the total daily dosage of the compounds of the present invention will be decided by the attending physician within the scope of sound medical judgment.
- the particular therapeutically effective dosage level will depend upon a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the particular compound employed; the particular composition employed; age, weight, general health, sex, and diet of the patient; time of administration, route of administration, and excretion rate of the particular compound employed; duration of treatment; drugs used in combination or concomitantly with the particular compound employed; and Similar factors well known in the medical field. For example, it is the practice in the art to start with a dose of the compound below that required to obtain the desired therapeutic effect and gradually increase the dose until the desired effect is obtained.
- substituted refers to two situations in which one or more hydrogen atoms of the substituted group may be "substituted” or “unsubstituted” by one or more substituents.
- variable R when any variable (substituent R) appears more than once in the composition or structure of the compound, its definition in each case is independent, and the substituent may be the same or different; in general, the Variables can be selected from the same or different substituent groups in the same technical scheme; for example, when m is 2 in general formula (I), ring A is substituted with two R groups, wherein each R is defined independently of each other ; for example, the R 3 is substituted with one or more R a , wherein each R a is also independent of each other. Furthermore, combinations of substituents and/or variables are preferably only present if such combinations result in stable compounds.
- substituent R 4 can be substituted at any position on the benzene ring.
- any adjacent two R a are connected and the atoms to which they are connected together form a heterocycle
- “any adjacent” means that the two R a are connected at the vicinal positions of the substituted group, respectively on the atom.
- the structure types such as When two R a are substituents of heterocyclyl or cycloalkyl, the structure type is as
- nitrogen atoms are present on the compounds of the present invention, these nitrogen atoms can be converted to N-oxides by treatment with an oxidizing agent to obtain other compounds of the present invention. Accordingly, unless otherwise specified, all shown and claimed nitrogen atom-containing groups are understood to encompass both non-nitroxide groups and their nitroxide groups (N ⁇ O).
- halogen in the present invention refers to a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- Alkyl refers to a branched or straight-chain saturated aliphatic alkane having a specified number of carbon atoms with one hydrogen-derived group removed.
- C 1-10 alkyl is meant to include C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 alkyl, including “C 1-6 "Alkyl", “C 1-4 alkyl", “C 1-3 alkyl”; specific examples include but are not limited to: methyl, ethyl, n-propyl, isopropyl, sec-butyl, 2-methyl butyl, 1,1-dimethylbutyl, etc.
- alkylene refers to a branched or straight-chain saturated aliphatic alkane having a specified number of carbon atoms, a group derived by removing two hydrogens.
- C 1-10 alkylene includes C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 alkylene, including “C 1-8 "Alkylene”, “C 1-6 alkylene”, “C 1-4 alkylene”, “C 3-4 alkylene”, “C 6-8 alkylene", “C 6-7 alkylene”"Alkylene”,"C 1-6 alkylene”; preferably, the "alkylene” in the present invention is a "straight-chain alkylene"; specific examples include but are not limited to: -CH 2 -, - CH2CH2-,- CH2CH2CH2 -,- CH ( CH3 ) CH2 - , - CH2CH2CH2CH2
- haloalkyl in the present invention refers to a group obtained by replacing the hydrogen in the alkyl group with one or more halogens, such as "fluoromethyl” including monofluoromethyl, difluoromethyl, trifluoromethyl ;
- the "halogenated alkyl group” in the present invention is “halogenated C 1-6 alkyl group” and “halogenated C 1-4 alkyl group”.
- Alkyl is as defined above.
- the “deuterated alkyl group” in the present invention refers to a group obtained by replacing the hydrogen in the alkyl group with one or more deuterium (D), such as DCH 2 -, D 2 CH-, D 3 C-; preferably Typically, the “deuterated alkyl group” in the present invention is “deuterated C 1-6 alkyl group” and “deuterated C 1-4 alkyl group”. Alkyl is as defined above.
- hydroxy C 1-6 alkyl group in the present invention refers to a group obtained by replacing the hydrogen in the alkyl group with one or more hydroxyl groups, such as HOCH 2 -, HOCH 2 -CH(OH)-, etc.; preferably Typically, the "hydroxy C 1-6 alkyl group” in the present invention is a hydroxy C 1-4 alkyl group.
- Alkyl is as defined above.
- NC-cycloalkyl in the present invention refers to a group obtained by substituting any hydrogen atom on a cycloalkyl with a cyano group, such as Wait. Cycloalkyl is as defined in this specification.
- cycloalkyl-(CH 2 )pO- when p is 0, the cycloalkyl group is connected to O through a chemical bond, that is, a cycloalkyl group-O- is formed.
- alkoxy in the present invention refers to an alkyl group as defined herein connected to other groups through an oxygen atom, ie "alkyl-O-".
- alkyl-O- Including "C 1-6 alkoxy” (structure is C 1-6 alkyl-O-), "C 1-4 alkoxy”, specific examples include but are not limited to methoxy, ethoxy, propoxy , 1-methylethoxy, butoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy
- the "alkoxy” in the present invention is a C 1-4 alkoxy group, more preferably a C 1-3 alkoxy group.
- L 1 and L 2 are specific "C 1-8 alkylene" and "C 1-6 alkylene", unless otherwise specified, the writing mode of the specific group does not limit its relationship with the two sides.
- L1 is The compounds include the following two:
- L2 is , the compounds include the following two:
- cycloalkyl group in the present invention refers to a saturated cyclic alkyl group derived from a cycloalkane by removing one hydrogen atom, including a monocyclic or polycyclic saturated hydrocarbon group;
- the polycyclic saturated hydrocarbon group refers to a group consisting of two or more Cyclic alkyl structures are polycyclic groups formed by spiro, bridge, condensed, etc. connections.
- the carbon atoms in the cycloalkyl group may be further oxo, ie to form C(O).
- a certain membered cycloalkyl group described herein can be understood as a monocyclic cycloalkyl group, and when it is a polycyclic ring, it will be specifically indicated as a spiro, fused or bridged ring group.
- the cycloalkyl group includes "3-8 membered cycloalkyl", “3-6 membered cycloalkyl” and "3-5 membered cycloalkyl".
- the cycloalkyl group is a monocyclic, saturated structure; specific examples include but are not limited to: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl.
- heterocyclic group in the present invention refers to a saturated cyclic group derived from the substitution of a ring carbon atom in a cycloalkyl by one or more heteroatoms, including a monocyclic or polycyclic heterocyclic group;
- Cyclic heterocyclic group refers to a polycyclic group formed by connecting a monocyclic heterocyclic group with other heterocyclic groups or cycloalkyl groups through spiro, bridge, condensed, etc.;
- the heteroatom is generally selected from N, O, S;
- the carbon atom or heteroatom in the heterocyclic group can be further oxo, that is to form C(O), N(O), SO, SO 2 ; preferably, the heteroatom is independently selected from 1 - 3 Ns and/or Os.
- a certain membered heterocyclic group described herein can be understood as a monocyclic heterocyclic group, and if it is a multi-heterocyclic group, it will be specifically indicated as a spiro, fused or bridged ring group; the heterocyclic group includes "3-8 membered heterocyclyl", “3-6 membered heterocyclyl", “3-5 membered heterocyclyl", “5-6 membered heterocyclyl”.
- the heterocyclic group is a monocyclic, saturated structure; specific examples include but are not limited to azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, morpholinyl and the like.
- the "heterocycle" reference applies this definition.
- aryl group in the present invention refers to a cyclic unsaturated and aromatic group formed by carbon atoms as ring atoms, which can be a single ring or a plurality of rings fused together.
- C6-10 membered aryl groups include, but are not limited to, phenyl, naphthyl.
- heteroaryl in the present invention refers to an aromatic monocyclic or polycyclic group containing one or more heteroatoms in the ring, and the heteroatoms are generally selected from N, O, and S; preferably, the The heteroatoms of are independently selected from 1-3 N and/or O, in addition, the N and S atoms may be optionally oxidized and the N atom may be optionally quaternized.
- the "heteroaryl group” includes "monocyclic heteroaryl group” and "fused ring heteroaryl group", and the said fused ring heteroaryl group means that two or more cyclic structures share two adjacent adjacent to each other. A group formed by atoms containing one or more heteroatoms and having overall aromaticity.
- heteroaryl described herein can generally be understood as a “monocyclic heteroaryl", such as the "5-6 membered heteroaryl” described herein, which also does not have the ability to form a fused ring heteroaryl. possibility; when it is “fused ring heteroaryl”, it will be specifically indicated as “fused” heteroaryl structure, such as "8-10-membered fused ring heteroaryl”.
- the heteroaryl group of the present invention is preferably a "nitrogen-containing heteroaryl group", preferably a "5- to 6-membered nitrogen-containing aryl group", and the heteroatom in the "nitrogen-containing heteroaryl group” contains at least one nitrogen atom, For example, only 1, 2, or 3 nitrogen atoms, or, 1 nitrogen atom and 1 or 2 other heteroatoms (eg, S and/or O atoms), or 2 nitrogen atoms and other 1 or 2 heteroatoms.
- heteroaryl group examples include, but are not limited to: furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, imidazolyl , pyrazolyl, etc.
- the present invention includes all isotopes of atoms occurring in the compounds of the present invention.
- Isotopes include atoms with the same atomic number but different mass numbers.
- isotopes of hydrogen include protium (often represented by H), deuterium (often represented by D), and tritium (often represented by T); isotopes of carbon include12C , 13C , and14C .
- Isotopically labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art, or by methods analogous to those described herein, using an appropriate isotopically labeled reagent in place of the otherwise employed unlabeled reagent.
- a stable compound or stable structure refers to a compound that is stable enough to undergo chemical reaction, isolated in useful purity, and can be formulated as an effective therapeutic drug.
- a preparation method of some compounds of the present invention is further provided, which comprises the following steps:
- X, R 1 , R 2 , R 3 , L 2 , R 4 , m, and ring A are as defined in the technical solution of the first aspect of the present invention.
- Hal is independently halogen, preferably Cl, Br;
- P is an amino protecting group, which can be derived from acid anhydride compounds, acid chloride compounds, halides, etc.
- Common protecting groups include but are not limited to: tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), 2-biphenyl -2-Propoxycarbonyl (BPoc), Phthalimido (pht), p-toluenesulfonyl (Tosyl), Trityl (Trityl), formyl (formyl) Fmoc, Alloc, Teoc, etc.; Preferred are Boc and Cbz.
- step 1
- the polar organic solvent includes but is not limited to one or more of the following: tetrahydrofuran, ether, N,N-dimethylformamide, dimethyl ether, N-methylpyrrolidone, dimethyl sulfoxide, acetonitrile .
- Described basic condition can be to add basic catalyst, described basic catalyst includes but not limited to following one or more: bis (trimethylsilyl) sodium amide, NaH, bis (trimethylsilyl) ) lithium amide, bis(trimethylsilyl) potassium amide, lithium diisopropylamide, n-butyl lithium, sec-butyl lithium, tert-butyl lithium, potassium tert-butoxide, sodium tert-butoxide, sodium methoxide, Inorganic bases such as sodium ethoxide, magnesium methyl bromide (chloride), magnesium ethyl bromide (chloride), magnesium sec-butyl bromide (chloride), and triethylamine, N,N-diisopropylethylamine, 4-dimethylaminopyridine, DBU (1,8-diazabicycloundec-7-ene) and other organic bases.
- the acidic conditions refer to the presence of organic acids and/or inorganic acids.
- inorganic acids can be used, preferably hydrochloric acid; organic acids can also be used, preferably trifluoroacetic acid.
- the intermediate 4 is added with a coupling catalyst and a metal chelate ligand under alkaline conditions, and the product is obtained by the reaction.
- Described basic condition can be to add basic catalyst, described basic catalyst includes but not limited to following one or more: cesium carbonate, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium phosphate, potassium tert-butoxide , Sodium tert-butoxide, bis(trimethylsilyl) lithium amide, bis(trimethylsilyl) potassium amide, triethylamine, N,N-diisopropylethylamine, DBU.
- Described coupling catalyst is selected from palladium catalyst, and described palladium catalyst is selected from tridibenzylideneacetone dipalladium, methanesulfonic acid (2-dicyclohexylphosphine)-3,6-dimethoxy-2', 4',6'-Triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (BrettPhos Pd G3), palladium acetate, Methanesulfonic acid (2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl- 2-yl)palladium(II) (XPhos Pd G3), methanesulfonic acid (2-dicyclohexylphosphino-2',6'
- the metal chelating ligand is selected from 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (xantphos), 2-(dicyclohexylphosphine)-3,6-dimethyl Oxy-2'-4'-6'-tri-1-propyl-11'-biphenyl (BrettPhos), 1,1'-binaphthyl-2,2'-bisdiphenylphosphine (BINAP), 2 -(Di-tert-butylphosphino)biphenyl (JohnPhos), 2-dicyclohexylphosphino-2'-(N,N-dimethylamine)-biphenyl (DavePhos), 2-dicyclohexylphosphino-2', 6'-Dimethoxybiphenyl (SPhos), 2-(di-tert-butylphosphine)-3,6-dimethoxy-2'-4'-6'tri-1-propy
- X is selected from CH;
- R 1 is selected from C 1-4 alkyl
- R 2 is selected from C 1-4 alkoxy
- R 3 is selected from 5-6 membered heteroaryl optionally substituted by 1-2 R a ;
- R a is selected from hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy;
- Ring A is selected from phenyl, pyridyl, pyrimidinyl;
- R 4 is selected from hydrogen, halogen, C 1-4 alkyl
- n is selected from 0 and 1.
- R 2 is selected from -OCH 3 ;
- R 3 is selected from pyrazolyl, pyrimidinyl, pyridyl optionally substituted by 1-2 R a ;
- Ra is selected from hydrogen, F, -CH3 , -OCH3 , -O-CH( CH3 ) 2 .
- Y is -O-, -S-, -NH-;
- Ring A is selected from phenyl, pyridyl, pyrimidinyl;
- R 4 is selected from hydrogen, fluorine, -CH 3 ;
- n is selected from 0 and 1.
- the structure of intermediate 1 is: Wherein Y is -O-, -S-, -NR 7 -, -C(R 7 ) 2 -, -NR 7 -C(O)-, -OC(O)-, -S(O)-, - S(O) 2 -; R 7 is selected from hydrogen, C 1-4 alkyl, C 1-4 alkyl-C(O)-, -C(O)OCH 2 Ph, preferably, R 7 is selected from hydrogen , C 1-4 alkyl; q 1 , q 2 are each independently 0, 1, 2, 3, 4, preferably, the sum of q 1 and q 2 is 2-5, preferably 3 or 4.
- R 2 is selected from C 1-4 alkoxy
- R 3 is selected from 5-6 membered heteroaryl optionally substituted by 1-2 R a ;
- R a is selected from hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy;
- Y is -O-, -S-, -NH-;
- Ring A is selected from phenyl, pyridyl, pyrimidinyl;
- R 4 is selected from hydrogen, halogen, C 1-4 alkyl
- n is selected from 0 and 1.
- R 2 is selected from -OCH 3 ;
- R 3 is selected from pyrazolyl, pyrimidinyl, pyridyl optionally substituted by 1-2 R a ;
- Ra is selected from hydrogen, F, -CH3 , -OCH3 , -O-CH( CH3 ) 2 .
- Y is -O-, -S-, -NH-;
- Ring A is selected from phenyl, pyridyl, pyrimidinyl;
- R 4 is selected from hydrogen, fluorine, -CH 3 ;
- n is selected from 0 and 1.
- the intermediate 1a is selected from the structures shown below:
- R 2 , R 3 , R 4 , m, Ra , q 1 , q 2 , Y, P are as defined in any of the preceding schemes; preferably, Ra is selected from H, F, -CH 3 , -OCH 3 .
- G 1 and G 2 independently represent halogen, -C(O)R', NH 2 , OH, SH; R' represents OH or halogen;
- R 2 , R 3 , R 4 , m, ring A, q 1 , q 2 , Y, P are as defined in any of the preceding schemes.
- Intermediate A and intermediate B are subjected to condensation reaction under suitable conditions to obtain intermediate C, which is then reduced to obtain intermediate 1a.
- Described suitable conditions include but are not limited to: 1 Add basic catalyst, such as NaH, sodium hydroxide, potassium hydroxide, lithium hydroxide, bis (trimethylsilyl) sodium amide, bis (trimethylsilyl) Lithium amide, potassium bis(trimethylsilyl)amide, lithium diisopropylamide, n-butyllithium, sec-butyllithium, tert-butyllithium, potassium tert-butoxide, sodium tert-butoxide, sodium methoxide, ethanol Inorganic bases such as sodium, methyl bromide (chloride) magnesium, ethyl bromide (chloride) magnesium, sec-butyl bromide (chloride) magnesium and/or triethylamine, N,N-diisopropylethylamine, Organic bases such as 4-dimethylaminopyridine, DBU; 2 add dehydrating agent or condensing agent or coupling agent, specifically can be selected from: T3P
- the reduction includes: Pd/C reduction, ferric acid reduction, catalytic hydrogenation, sodium sulfide and thiosulfuric acid reduction, hydrazine Raney nickel hydrate reduction, and the like.
- R 2 is selected from C 1-4 alkoxy
- R 3 is selected from 5-6 membered heteroaryl optionally substituted by 1-2 R a ;
- R a is selected from hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy;
- Y is -O-, -S-, -NH-;
- Ring A is selected from phenyl, pyridyl, pyrimidinyl;
- R 4 is selected from hydrogen, halogen, C 1-4 alkyl
- n is selected from 0 and 1.
- R 2 is selected from -OCH 3 ;
- R 3 is selected from pyrazolyl, pyrimidinyl, pyridyl optionally substituted by 1-2 R a ;
- Ra is selected from hydrogen, F, -CH3 , -OCH3 , -O-CH( CH3 ) 2 .
- Y is -O-, -S-, -NH-;
- Ring A is selected from phenyl, pyridyl, pyrimidinyl;
- R 4 is selected from hydrogen, fluorine, -CH 3 ;
- n is selected from 0 and 1.
- intermediate 1a and intermediate 2 are further reacted to form the following structural compounds (for the preparation process, refer to formula (II) preparation method steps 1-3):
- R 1 , R 4 , m, Ra , q 1 , q 2 , P, Y, Hal, G1, G2, ring A are as defined in the previous scheme;
- the nomenclature of the title compound was converted from the compound structure by means of Chemdraw. If there is any inconsistency between the compound name and the compound structure, it can be determined by synthesizing relevant information and reaction routes; if it cannot be confirmed by other methods, the given compound structural formula shall prevail.
- the preparation methods of some compounds in the present invention refer to the preparation methods of the aforementioned similar compounds. Those skilled in the art should know that when using or referring to the preparation methods cited therein, the charging ratio of the reactants, the reaction solvent, and the reaction temperature can be appropriately adjusted according to the different reactants.
- the compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments enumerated below, embodiments formed in combination with other chemical synthesis methods, and those well known to those skilled in the art Equivalent to alternatives, preferred embodiments include, but are not limited to, the embodiments of the present invention.
- the structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) or/and liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts ([delta]) are given in parts per million (ppm). NMR was measured by Varian 400M or Bruker Ascend 400 nuclear magnetic instrument, and the solvent was deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated methanol (CD 3 OD), deuterated chloroform (CDCl 3 ) or heavy water ( D 2 O), the internal standard is tetramethylsilane (TMS).
- DMSO-d 6 deuterated dimethyl sulfoxide
- CD 3 OD deuterated methanol
- CDCl 3 deuterated chloroform
- D 2 O heavy water
- TMS tetramethylsilane
- LC-MS The determination of LC-MS was performed with Agilent 1260-6120B/6125B single quadrupole mass spectrometer mass spectrometer (ion source was electrospray ionization), and the column was Waters CORTECS column (C18, 2.7um, 4.6*30mm).
- HPLC assay used Waters H-class UPLC and Agilent 1260 infinity II high performance liquid chromatography.
- the thin-layer chromatography silica gel plate is made of GF254 silica gel plate of Yantai Jiangyou Silica Gel Development Co., Ltd. or GF254 silica gel plate of Rushan Shangbang New Materials Co., Ltd. Generally used in the chemical industry 200 ⁇ 300 mesh silica gel as the carrier.
- the starting materials in the examples of the present invention are known and commercially available, or can be synthesized using or according to methods known in the art.
- the component ratios of the mixed solvent or column chromatography eluent used in the examples of the present invention are all volume ratios.
- the unit “M” represents "mol/L", which is the concentration of the reagent.
- the first step the preparation of 4-(2-hydroxyethyl)-2-nitrophenol
- the second step the preparation of 2-(4-methoxy-3-nitrophenyl) ethanol
- the third step the preparation of tert-butyl (6-((4-methoxy-3-nitrophenethoxy) methyl) pyridin-2-yl carbamate
- the fourth step the preparation of tert-butyl-(6-((3-amino-4-methoxyphenethoxy)methyl)-pyridin-2-yl carbamate
- the fifth step tert-butyl-(6-((3-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-4-methoxyphenethoxy)methyl)pyridine- Preparation of 2-yl)carbamate
- Step 6 4-((5-(2-((6-aminopyridin-2-yl)methoxy)ethyl)-2-methoxyphenyl)amino)-6-chloro-N-methyl Preparation of pyridazine-3-carboxamide
- the seventh step 5 6 -methoxy-N-methyl-8-oxo-2,4-diaza-3(3,5)-pyridazine-1(2,6)-pyridine-5( Preparation of 1,3)-benzocyclononane-3 6 -carboxamide
- the first step the preparation of 2-(4-fluoro-3-nitro-phenyl)ethanol
- the third step preparation of tert-butyl (6-((4-(methylthio)-3-nitrophenethoxy)methyl)pyridin-2-yl carbamate
- the fourth step the preparation of tert-butyl (6-((3-amino-4-(methylthio) phenethoxy) methyl) pyridin-2-yl) carbamate
- the fifth step tert-butyl (6-((3-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-4-(methylthio)phenethoxy ) methyl) pyridin-2-2-yl) carbamate preparation
- Step 6 4-((5-(2-(((6-aminopyridin-2-yl)methoxy)ethyl)-2-(methylthio)phenyl)amino)-6-chloro- Preparation of N-methylpyridazine-3-carboxamide
- the seventh step N-methyl-56-(methylthio)-8 - oxa-2,4-diaza-3(3,5)-pyridazine-1(2,6)-pyridine- Preparation of 5(1,3)-benzocyclononane-3 6 -carboxamide
- Example 6-1 and Example 6-2 are identical to Example 6-1 and Example 6-2:
- the first step the preparation of 2-bromo-4-(2-hydroxyethyl) phenol
- the third step the preparation of methyl 5-(2-acetoxyethyl)-2-hydroxybenzoate
- the fourth step the preparation of methyl 5-(2-acetoxyethyl)-2-hydroxy-3-nitrobenzoate
- the fifth step the preparation of methyl 5-(2-acetoxyethyl)-2-methoxy-3-nitrobenzoate
- Methyl 5-(2-acetoxyethyl)-2-hydroxy-3-nitrobenzoate (1.7 g, 6.0021 mmol) was dissolved in N,N-dimethylformamide (20 mL), followed by adding carbonic acid Potassium (1.66 g, 12 mmol) and methyl iodide (1022.33 mg, 7.20 mmol), the reaction solution was reacted at 70° C. for 8 hours.
- the sixth step the preparation of methyl 5-(2-hydroxyethyl)-2-methoxy-3-nitrobenzoate
- the seventh step the preparation of 5-(2-hydroxyethyl)-2-methoxy-3-nitrobenzamide
- Step 8 Preparation of 2-(4-methoxy-3-nitro-5-(1H-1,2,4-triazol-3-yl)phenyl)ethane-1-ol
- Step 10 2-Bromo-6-((4-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)-5-nitrophenethoxy ) methyl) pyridine preparation
- the thirteenth step tert-butyl (6-((3-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-4-methoxy-5-(1 - Preparation of methyl-1H-1,2,4-triazol-3-yl)phenethoxy)methyl)pyridin-2-yl)carbamate
- tert-Butyl (6-((3-amino-4-methoxy-5-(1-methyl-1H-1,2,4-triazol-3-yl)phenethoxy)methyl) Pyridin-2-yl)carbamate (100 mg, 0.22 mmol) was dissolved in tetrahydrofuran (3 mL), followed by the addition of 4,6-dichloro-N-methylpyridazine-3-carboxamide (68 mg, 0.33 mmol) and Sodium bis(trimethylsilyl)amide (0.3 mL), the reaction solution was reacted at room temperature for 10 minutes. After the reaction was completed, water (5 mL) was added to quench, and dichloromethane was extracted (3 ⁇ 30 mL).
- the fifteenth step 56 -methoxy-N-methyl-55-(1-methyl-1H-1,2,4-triazol- 3 -yl)-8-oxo-2,4 - Preparation of Diaza-3(3,5)-pyridazine-1(2,6)-pyridine-5(1,3)-benzocyclononane - 36-carboxamide (Compound 6-1)
- the first step tert-butyl (6-((3-((6-chloro-3-((methyl-d3)carbamoyl)pyridazin-4-yl)amino)-4-methoxy-5 Preparation of -(1-methyl-1H-1,2,4-triazol-3-yl)phenethoxy)methyl)pyridin-2-yl)carbamate
- tert-Butyl (6-((3-amino-4-methoxy-5-(1-methyl-1H-1,2,4-triazol-3-yl)phenethoxy)methyl) Pyridin-2-yl)carbamate (180 mg, 0.395 mmol) was dissolved in tetrahydrofuran (3 mL), followed by the addition of 4,6-dichloro-N-methylpyridazine-3-carboxamide (162 mg, 0.79 mmol) and Sodium bis(trimethylsilyl)amide (0.3 mL), the reaction solution was reacted at room temperature for 10 minutes. After the reaction was completed, water (5 mL) was added to quench, and dichloromethane was extracted (3 ⁇ 30 mL).
- the second step 4-((5-(2-((6-aminopyridin-2-yl)methoxy)ethyl)-2-methoxy-3-(1-methyl-1H-1, Preparation of 2,4-triazol-3-yl)phenyl)amino)-6-chloro-N-(methyl-d3)pyridazine-3-carboxamide
- the third step 56 -methoxy-N-methyl-55-(1-methyl-1H-1,2,4-triazol- 3 -yl)-8-oxo-2,4- Preparation of Diaza-3(3,5)-pyridazine-1(2,6)-pyridine-5(1,3)-benzocyclononane - 36-carboxamide
- the first step preparation of ethyl 4-methoxy-3-(1-methyl-1H-pyrazol-3-yl)-5-nitrophenylacetate
- the second step preparation of 2-(4-methoxy-3-(1-methyl-1H-pyrazol-3-yl)-5-nitrophenyl)ethyl-1-ol
- the fourth step tert-butyl (6-((3-amino-4-methoxy-5-(1-methyl-1H-pyrazol-3-yl) phenethoxy) methyl) pyridine-2 - group) preparation of carbamates
- the fifth step tert-butyl (6-((3-((6-chloro-3-(formamido)pyridazin-4-yl)amino)-4-methoxy-5-(1-methyl) Preparation of -1H-pyrazol-3-yl)phenethoxy)methyl)pyridin-2-yl)carbamate
- Step 6 4-((5-(2-((6-aminopyridin-2-yl)methoxy)ethyl)-2-methoxy-3-(1-methyl-1H-pyrazole Preparation of -3-yl)phenyl)amino)-6-chloro-N-methylpyridazine-3-carbamate
- the seventh step 56 -methoxy-N-methyl-55-(1-methyl-1H-pyrazol- 3 -yl)-8-oxa-2,4-diaza-3( Preparation of 3,5)-pyridazine 1(2,6)-pyridine-5(1,3)-benzocyclononane-3 6 -carboxamide
- the first step tert-butyl (6-((3-((6-chloro-3-((methyl-d 3 )carboxamido)pyridazin-4-yl)amino)-4-methoxy- Preparation of 5-(1-methyl-1H-pyrazol-3-yl)phenethoxy)methyl)pyridin-2-yl)carbamate
- Step 2 4-((5-(2-((6-aminopyridin-2-yl)methoxy)ethyl)-2-methoxy-3-(1-methyl-1H-pyrazole Preparation of -3-yl)phenyl)amino)-6-chloro-N-(methyl- d3 )pyridazine-3-carbamate
- the third step 56 -methoxy-N-(methyl- d3 )-55-( 1 -methyl-1H-pyrazol-3-yl)-8-oxa-2,4-di
- the first step the preparation of tert-butyl (tert-butoxycarbonyl) (5-fluoro-6-methylpyridin-2-yl) carbamate
- the second step the preparation of tert-butyl (6-(bromomethyl)-5-fluoropyridin-2-yl) (tert-butoxycarbonyl) carbamate
- the fifth step tert-butyl (6-((3-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-4-methoxy-5-(1- Preparation of methyl-1H-pyrazol-3-yl)phenylethoxy)methyl)-5-fluoropyridin-2-yl)carbamate
- Step 6 4-((5-(2-((6-amino-3-fluoropyridin-2-yl)methoxy)ethyl)-2-methoxy-3-(1-methyl- Preparation of 1H-pyrazol-3-yl)phenyl)amino)-6-chloro-N-methylpyridazine-3-carbamate
- Step 7 15 -Fluoro-56-methoxy-N-methyl-55-(1-methyl-1H-pyrazol- 3 -yl)-8 - oxa-2,4-di Preparation of aza-3(3,5)-pyridazine-1(2,6)-pyridine-5(1,3)-benzocyclononane - 36-carboxamide
- the first step preparation of (4-methoxy-3-(1-methyl-1H-pyrazol-3-yl)-5-nitrophenethyl) tert-butyl carbamate
- the second step the preparation of (4-methoxy-3-(1-methyl-1H-pyrazol-3-yl)-5-nitrophenethyl) (methyl) carbamate tert-butyl ester
- the third step 2-(4-methoxy-3-(1-methyl-1H-pyrazol-3-yl)-5-nitrophenyl)-N-methylethane-1-amine preparation
- tert-butyl (6-(((4-methoxy-3-(1-methyl-1H-pyrazol-3-yl)-5-nitrophenethyl ) (methyl) amino) methyl) pyridin-2-yl carbamate preparation
- the fifth step tert-butyl (6-((((3-amino-4-methoxy-5-(1-methyl-1H-pyrazol-3-yl) phenethyl) (methyl) amino ) methyl)pyridin-2-yl)(tert-butoxycarbonyl)carbamate preparation
- the sixth step tert-butyl (6-((((3-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-4-methoxy-5-( Preparation of 1-Methyl-1H-pyrazol-3-yl)phenethyl)(methyl)amino)methyl)pyridin-2-ylcarbamate
- Step 7 4-((5-(2-((((((6-aminopyridin-2-yl)methyl)(methyl)amino)ethyl)-2-methoxy-3-(1 Preparation of -methyl-1H-pyrazol-3-yl)phenyl)amino)-6-chloro-N-methylpyridazine-3-carboxamide
- the eighth step 56 - methoxy-N,8-dimethyl-55-( 1 -methyl-1H-pyrazol-3-yl)-2,4,8-triaza-3( Preparation of 3,5)-pyridazine-1(2,6)-pyridine-5(1,3)-benzocyclononane-3 6 -carboxamide
- the first step the preparation of 2-[4-methoxy-3-(1-methylpyrazol-3-yl)-5-nitrophenyl]ethyl 4-toluenesulfonate
- the second step the preparation of 2-[4-methoxy-3-(1-methylpyrazol-3-yl)-5-nitrophenyl]ethanethiol
- the third step tert-butyl ⁇ 6-[( ⁇ 2-[4-methoxy-3-(1-methylpyrazolyl-3-yl)-5-nitrophenyl]ethyl ⁇ sulfonyl ) methyl]pyridin-2-yl ⁇ carbamate preparation
- the fifth step tert-butyl (6-((3-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-4-methoxy-5-(1- Preparation of methyl-1H-pyrazol-3-yl)phenethyl)thio)methyl)pyridin-2-yl)carbamate
- the fifth step 4-((5-(2-((6-aminopyridin-2-yl)methyl)thio)ethyl)-2-methoxy-3-(1-methyl-1H- Preparation of pyrazol-3-yl)phenyl)amino)-6-chloro-N-methylpyridazine-3-carboxamide
- the sixth step 56-methoxy-N-methyl-55-(1-methyl-1H-pyrazol- 3 -yl)-8-thi-2,4-diaza-3(3 Preparation of ,5)-pyridazine-1(2,6)-pyridine-5(1,3)-benzocyclononane-3 6 -carboxamide
- the first step preparation of methyl 6-(bis(tert-butoxycarbonyl)amino)picolinate
- the second step the preparation of 6-((tert-butoxycarbonyl)amino)picolinic acid
- the third step 2-(4-methoxy-3-(1-methyl-1H-pyrazol-3-yl)-5-nitrophenethyl)isoindoline-1,3-dione preparation
- the fourth step the preparation of 2-(4-methoxy-3-(1-methyl-1H-pyrazol-3-yl)-5-nitrophenyl)ethan-1-amine
- the seventh step tert-butyl (6-((3-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-4-methoxy-5-(1- Preparation of methyl-1H-pyrazol-3-yl)phenethylcarbamoyl)pyridin-2-ylcarbamate
- tert-Butyl (6-((3-amino-4-methoxy-5-(1-methyl-1H-pyrazol-3-yl)phenethyl)carbamoyl)pyridin-2-yl) Carbamate 7 (350 mg, 0.75 mmol), 4,6-dichloro-N-methylpyridazine-3-carboxamide (230 mg, 1.12 mmol) were dissolved in tetrahydrofuran (10 mL), and bisulfite was added dropwise at room temperature Sodium (trimethylsilyl)amide (1.9 mL, 3.75 mmol, 2M in tetrahydrofuran). The mixture was stirred at 25°C for 1 hour.
- the eighth step 4-((5-(2-(6-aminopyridinecarboxamido)ethyl)-2-methoxy-3-(1-methyl-1H-pyrazol-3-yl)benzene Preparation of yl)amino)-6-chloro-N-methylpyridazine-3-carboxamide
- Step 9 56 - methoxy-N-methyl-55-( 1 -methyl-1H-pyrazol-3-yl)-9-oxo-2,4,8-triaza- Preparation of 3(3,5)-pyridazine-1(2,6)-pyridine-5(1,3)-benzocyclononyl-3 6 -carboxamide
- reaction mixture was heated to 130°C in a closed tube and stirred for 2 hours. After the reaction was completed, it was filtered and concentrated to obtain the crude product. The crude product was purified by preparative liquid chromatography to give the title compound (26 mg, 14% yield).
- the first step tert-butyl (6-((3-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-4-methoxy-5-(1- Preparation of methyl-1H-pyrazol-4-yl)phenethoxy)methyl)pyridin-2-yl)carbamate
- Step 2 4-((5-(2-(((6-aminopyridin-2-yl)methoxy)ethyl)-2-methoxy-3-(1-methyl-1H-pyridine Preparation of oxazol-4-yl)phenyl)amino)-6-chloro-N-methylpyridazine-3-carboxamide
- the third step 56 -methoxy-N-methyl-55-(1-methyl-1H-pyrazol- 4 -yl)-8-oxa-2,4-diaza-3( Preparation of 3,5)-pyridazine-1(2,6)-pyridine-5(1,3)-benzocyclononyl - 36-carboxamide
- the first step the preparation of (tert-butoxycarbonyl) (8-hydroxyquinoline-2-hydroxy) tert-butyl carbamate
- the fifth step 4-((5-(2-(((2-aminoquinolin-8-yl)oxy)ethyl)-2-methoxy-3-(1-methyl-1H-pyridine Preparation of oxazol-3-yl)phenyl)amino)-6-chloro-N-methylpyridazine-3-carboxamide
- the sixth step 56-methoxy-N-methyl-55-(1-methyl-1H-pyrazol- 3 -yl)-8-oxa-2,4-diaza-1( Preparation of 2,8)-quinoline-3(3,5)-pyridazine 5(1,3)-benzocyclooctane-3 6 -carboxamide
- the first step the preparation of methyl 6-amino-3-methylpicolinate
- the second step the preparation of 6-(bis(tert-butoxycarbonyl)amino)-3-methylpicolinate methyl ester
- the third step the preparation of (6-(hydroxymethyl)-5-methylpyridin-2-yl) tert-butyl carbamate
- the fourth step the preparation of (6-(bromomethyl)-5-methylpyridin-2-yl) tert-butyl carbamate
- the seventh step tert-butyl (6-((3-((6-chloro-3-(methylcarbamoyl)pyridazin-4-yl)amino)-4-methoxy-5-(1- Preparation of methyl-1H-pyrazol-3-yl)phenethoxy)methyl)-5-methylpyridin-2-yl)carbamate
- Step 8 4-((5-(2-(((6-amino-3-methylpyridin-2-yl)methoxy)ethyl)-2-methoxy-3-(1-methyl) Preparation of yl-1H-pyrazol-3-yl)phenyl)amino)-6-chloro-N-methylpyridazine-3-carboxamide
- the ninth step 56 -methoxy-N, 15 -dimethyl-55-(1-methyl-1H-pyrazol- 3 -yl)-8-oxa-2,4-diaza Preparation of Hetero-3(3,5)-pyridazine-1(2,6)-pyridine-5(1,3)-benzocyclononane - 36-carboxamide
- the first step the preparation of 4,6-dichloro-N-methylpyridine-3-carboxamide
- the second step tert-butyl (6-((3-((2-chloro-5-(methylcarbamoyl)pyridin-4-yl)amino)-4-methoxy-5-(1-methyl) Preparation of yl-1H-pyrazol-3-yl)phenylethoxy)methyl)pyridin-2-yl)carbamate
- the third step 4-((5-(2-((6-aminopyridin-2-yl)methoxy)ethyl)-2-methoxy-3-(1-methyl-1H-pyrazole Preparation of -3-yl)phenyl)amino)-6-chloro-N-methylnicotinamide
- the fourth step 56 -methoxy-N-methyl-55-(1-methyl-1H-pyrazol- 3 -ethyl)-8-oxa-2,4-diaza-1 Preparation of (2,6),3(2,4)-bipyridine- 5 (1,3)-benzocyclononane-35-carboxamide
- the first step preparation of ethyl 2-(4-methoxy-3-nitro-5-(pyrimidin-2-yl)phenyl)acetate
- the second step preparation of 2-(4-methoxy-3-nitro-5-(pyrimidin-2-yl)phenyl)ethanol
- the fifth step tert-butyl (6-((2-(3-((6-chloro-3-(methylcarbamoyl)pyridazin 4-yl)amino)-4-methoxy-5-( Preparation of pyrimidin-2-yl)phenyl)ethoxy]methyl)pyridin-2-yl)carbamate
- Step 6 4-((5-(2-(((6-aminopyridin-2-yl)methoxy)ethyl)-2-methoxy-3-(pyrimidin-2-yl)phenyl ) Amino)-6-chloro-N-methylpyridazine-3-carboxamide preparation
- Step 7 56 -methoxy-N-methyl-55-(pyrimidin- 2 -yl)-8-oxa-2,4-diaza-3(3,5)-pyridazine-1 Preparation of (2,6)-pyridine- 55 (1,3)-benzocyclononane - 36-carboxamide
- N-(3-Amino-4-methoxy-5-(1-methyl-1H-pyrazol-3-yl)phenethyl)cyclopropane-1,1-dicarboxamide 110 mg, 0.30 mmol
- 4,6-Dichloro-N-methylpyridazine-3-carboxamide 126 mg, 0.61 mmol
- tetrahydrofuran 10 mL
- sodium bis(trimethylsilyl)amide 0.62 mmol
- the second step 6'-methoxy-N-methyl-5'-(1-methyl-1H-pyrazol-3-yl)-7', 9'-dioxospiro[cyclopropane-1, Preparation of 8'-2,6,10-triaza-1(4,2)-pyridine-3(1,3)-benzocyclodecane]-5'-carboxamide
- N-(3-((2-Chloro-5-(methylcarbamoyl)pyridin-4-yl)amino)-4-methoxy-5-(1-methyl-1H-pyrazole-3- yl)phenethyl)cyclopropane-1,1-dicarboxamide (30 mg, 0.05 mmol), cesium carbonate (111 mg, 0.34 mmol), tris(dibenzylideneacetone)dipalladium (5 mg, 0.001 mmol), 4 ,5-Bisdiphenylphosphine-9,9-dimethylxanthene (6 mg, 0.01 mmol) was mixed in 1,4-dioxane (10 mL).
- reaction mixture was heated to 130°C in a closed tube and stirred for 12 hours. After the reaction was completed, it was filtered and concentrated to obtain the crude product. The crude product was purified by preparative liquid chromatography to give the title compound (1.0 mg, 2% yield).
- the first step tert-butyl (6-((3-((6-chloro-3-(methylcarbamoyl)pyridin-4-yl)amino)-4-methoxy-5-(1-methyl) Preparation of -1H-1,2,4-triazol-3-yl)phenethoxy)methyl)pyridin-2-yl)carbamate
- tert-Butyl (6-((3-amino-4-methoxy-5-(1-methyl-1H-1,2,4-triazol-3-yl)phenethoxy)methyl) Pyridin-2-yl)carbamate (100 mg, 0.22 mmol) was dissolved in tetrahydrofuran (3 mL), followed by the addition of 4,6-dichloro-N-methylpyridazine-3-carboxamide (90 mg, 0.44 mmol) and Sodium bis(trimethylsilyl)amide (0.3 mL), the reaction solution was reacted at room temperature for 10 minutes.
- the second step 4-((5-(2-((6-aminopyridin-2-yl)methoxy)ethyl)-2-methoxy-3-(1-methyl-1H-1, Preparation of 2,4-triazol-3-yl)phenyl)amino)-6-chloro-N-methylnicotinamide
- the third step 56 -methoxy-N-methyl-55-(1-methyl-1H-1,2,4-triazol- 3 -yl)-8-oxo-2,4- Preparation of Diaza-1(2,6),3(2,4)-bipyridine- 5 (1,3)-benzocyclononane-35-carboxamide
- the first step tert-butyl (6-((3-((2-chloro-5-((methyl-d3)carbamoyl)pyridin-4-yl)amino)-4-methoxy-5- Preparation of (1-methyl-1H-1,2,4-triazol-3-yl)phenethoxy)methyl)pyridin-2-yl)carbamate
- tert-Butyl (6-((3-amino-4-methoxy-5-(1-methyl-1H-1,2,4-triazol-3-yl)phenethoxy)methyl) Pyridin-2-yl)carbamate (100 mg, 0.22 mmol) was dissolved in tetrahydrofuran (3 mL), followed by the addition of 4,6-dichloro-N-methylpyridazine-3-carboxamide (91 mg, 0.43 mmol) and Sodium bis(trimethylsilyl)amide (0.3 mL), the reaction solution was reacted at room temperature for 10 minutes.
- the second step 4-((5-(2-((6-aminopyridin-2-yl)methoxy)ethyl)-2-methoxy-3-(1-methyl-1H-1, Preparation of 2,4-triazol-3-yl)phenyl)amino)-6-chloro-N-(methyl-d3)nicotinamide
- the third step 5 6 -methoxy-N-(methyl-d3)-5 5- (1-methyl-1H-1,2,4-triazol-3-yl)-8-oxo- Preparation of 2,4-diaza-1(2,6),3(2,4)-bipyridine-5(1,3)-benzocyclononane-3 5 -carboxamide
- the first step preparation of ethyl 4-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-5-nitrophenylacetate
- the second step preparation of 2-(4-methoxy-3-(1-methyl-1H-pyrazol-4-yl)-5-nitrophenyl)-1-ethanol
- the fourth step tert-butyl (6-((3-amino-4-methoxy-5-(1-methyl-1H-pyrazol-4-yl) phenethoxy) methyl) pyridine-2 - group) preparation of carbamates
- the fifth step tert-butyl (6-((3-((2-chloro-5-(methylcarbamoyl)pyridin-4-yl)amino)-4-methoxy-5-(1-methyl) Preparation of yl-1H-pyrazol-4-yl)phenethoxy)methyl)pyridin-2-yl)carbamate
- Step 6 4-((5-(2-(((6-aminopyridin-2-yl)methoxy)ethyl)-2-methoxy-3-(1-methyl-1H-pyridine Preparation of azol-4-yl)phenyl)amino)-6-chloro-N-methylnicotinamide
- the seventh step 56 -methoxy-N-methyl-55-(1-methyl-1H-pyrazol- 4 -yl)-8-oxa-2,4-diaza-1( Preparation of 2,6),3(2,4)-bipyridine-5(1,3)-phenylcyclononyl-3 5 -carboxamide
- the first step tert-butyl (6-((3-((6-chloro-3-((methyl-d 3 )carbamoyl)pyridazin-4-yl)amino)-4-methoxy- Preparation of 5-(pyrimidin-2-yl)phenethoxy)methylpyridin-2-ylcarbamate
- tert-Butyl (6-((3-amino-4-methoxy-5-(pyrimidin-2-yl)phenethoxy)methyl)pyridin-2-yl)carbamate (200 mg, 0.44 mmol) and 4,6-dichloro-N-(methyl-d 3 )pyridazine-3-carboxamide (273 mg, 1.32 mmol) were dissolved in tetrahydrofuran (10 mL), and bis(trimethylsilyl) was slowly added dropwise ) sodium amide (2M, 1.3 mL, 2.65 mmol), and the mixture was stirred at 25°C for 10 minutes.
- Step 2 4-((5-(2-(((6-aminopyridin-2-yl)methoxy)ethyl)-2-methoxy-3-(pyrimidin-2-yl)phenyl ) amino)-6-chloro-N-(methyl-d 3 ) pyridazine-3-carboxamide preparation
- the third step 56 -methoxy-N-(methyl- d3 )-55-(pyrimidin- 2 -yl)-8-oxa-2,4-diaza-3(3,5 Preparation of )-pyridazine-1(2,6)-pyridine-5(1,3)-benzocyclononane-3 6 -carboxamide
- the first step the preparation of 2-(3-bromo-4-methoxy-5-nitrophenyl) ethan-1-ol
- the second step the preparation of (6-((3-bromo-4-methoxy-5-nitrophenethoxy)methyl)pyridin-2-yl)carbamic acid tert-butyl ester
- reaction was stirred at 90°C for 2 hours. After the reaction was completed, the reaction solution was filtered, the filtrate was concentrated under reduced pressure, water was added and extracted with ethyl acetate (20 mL ⁇ 3), the combined organic layers were washed with brine (20 mL ⁇ 2), dried over anhydrous sodium sulfate and concentrated under reduced pressure.
- Step 7 4-((5-(2-((6-aminopyridin-2-yl)methoxy)ethyl)-2-methoxy-3-(5-methylpyrimidin-2-yl )Phenyl)amino)-6-chloro-N-methylnicotinamide preparation
- Step 8 56 -methoxy-N-methyl-55-( 5 -methylpyrimidin-2-yl)-8-oxa-2,4-diaza-1(2,6) Preparation of ,3(2,4)-bipyridine-5(1,3)-benzocyclononane-3 5 -carboxamide
- the first step preparation of ethyl 4-methoxy-3-(5-methoxypyrimidin-2-yl)-5-nitrophenylacetate
- the second step preparation of 2-(4-methoxy-3-(5-methoxypyrimidin-2-yl)-5-nitrophenyl)ethanol
- the fourth step tert-butyl (6-((4-methoxy-3-(5-methoxypyrimidin-2-yl)-5-nitrophenylethoxy)methyl)pyridine-2- base) preparation of carbamates
- the sixth step tert-butyl (6-((3-((2-chloro-5-(methylcarbamoyl)pyridin-4-yl)amino)-4-methoxy-5-(5-methyl) Preparation of oxypyrimidin-2-yl)phenylethoxy)methyl)pyridin-2-yl)carbamate
- Step 7 4-((5-(2-((6-aminopyridin-2-yl)methoxy)ethyl)-2-methoxy-3-(5-methoxypyrimidine-2- Preparation of yl)phenyl)amino)-6-chloro-N-methylnicotinamide
- the eighth step 56-methoxy- 55- ( 5 -methoxypyrimidin-2-yl)-N-methyl-8-oxa-2,4-diaza-1(2,6 Preparation of ),3(2,4)-bipyridine-5(1,3)-benzocyclononane-3 5 -carboxamide
- the following specific embodiments will further describe the inhibitory effect of the compounds of the present invention on TYK2 kinase or TYK2 signaling pathway and other in vitro and in vivo effects, so as to show that the compounds of the present invention can be effectively used for the treatment of TYK2 target-related diseases.
- the beneficial effects of the compounds of the present invention include but are not limited to the following specific implementation contents.
- TR-FRET fluorescence resonance energy transfer
- the compound dilution plate was equipped with a compound concentration of 200 times the final concentration. According to the 27-fold ratio dilution method, diluted from the highest concentration point, a total of 4 concentration points, and transferred to the Echo plate.
- the compound dilution plate is equipped with a compound concentration of 100 times the final concentration. According to the 27-fold ratio dilution method, the compound is diluted from the highest concentration point, a total of 4 concentration points, and transferred to the Echo plate.
- the compounds of the examples of the present invention have good binding activity to TYK2 JH2 pseudokinase, and their binding activity does not exceed 30nM; when the binding activity is less than 1nM, it is represented by letter A; when 1nM ⁇ binding activity ⁇ 5nM, it is represented by letter B ; When the binding activity is >5nM, it is represented by the letter C; the specific results are shown in Table 1.
- the compounds of the examples of the present invention have no inhibitory activity on TYK2 JH1 kinase domain (IC 50 is preferably greater than 10 ⁇ M); no inhibitory activity or weak inhibitory activity on JAK1/2/3 (IC 50 is greater than 3 ⁇ M, preferably greater than 10 ⁇ M).
- Human PBMCs were purchased from Miaoshun (Shanghai) Biotechnology Co., Ltd.
- Fix buffer I Perm buffer III were purchased from BD Biosciences.
- FITC CD3 antibody was purchased from Biolegend Company.
- Alexa647pSTAT5 (pY694) antibody was purchased from BD Biosciences.
- Generic type I IFN ⁇ protein was purchased from R&D Systems.
- the 96-well U-shaped cell culture plate was purchased from Coring Company.
- the pipette was purchased from RAMIN Company,
- Fortessa (LSRFortessa) analytical flow cytometer was purchased from BD.
- PBMC cells for analysis were thawed and suspended in 1640 medium containing 10% serum, and incubated in a carbon dioxide incubator for 1 hour.
- Fixation Add 110 ⁇ L of preheated Fix buffer I, and incubate in a carbon dioxide incubator for 10 minutes.
- Membrane rupture add 150mL Perm buffer III and incubate on ice for 30 minutes.
- Antibody incubation add diluted FITC-CD3 and Alexa647pSTAT5 (pY694) antibodies (100 ⁇ L/well) to each well, and incubate at room temperature for 1 hour.
- MFI mean fluorescence intensity
- the IC 50 of the compounds shown in the examples of the present invention in the inhibition of cellular TYK2 signaling pathway is no more than 10 ⁇ M; when IC 50 ⁇ 50 nM, it is represented by letter A; when 50 nM ⁇ IC 50 ⁇ 100 nM , represented by letter B; when IC 50 >100nM, represented by letter C; see Table 2 for specific results.
- Human PBMCs were purchased from Miaoshun (Shanghai) Biotechnology Co., Ltd.
- Fix buffer I Perm buffer III were purchased from BD Biosciences.
- FITC CD3 antibody was purchased from Biolegend Company.
- Alexa647 pSTAT5 (pY694) antibody was purchased from BD Biosciences.
- IL-2 protein was purchased from Nearshore Protein Technology Co., Ltd.
- the 96-well U-shaped cell culture plate was purchased from Coring Company.
- a centrifuge (5810R) was purchased from Eppendorf.
- Fortessa (LSRFortessa) analytical flow cytometer was purchased from BD.
- PBMC cells for analysis were thawed and suspended in 1640 medium containing 10% serum, and incubated in a carbon dioxide incubator for 1 hour.
- Fixation Add 110 ⁇ L of preheated Fix buffer I, and incubate in a carbon dioxide incubator for 10 minutes.
- Membrane rupture add 150 ⁇ L Perm buffer III and incubate on ice for 30 minutes.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
L'invention concerne un composé de formule (II') en tant qu'inhibiteur de TYK2 macrocyclique, un sel pharmaceutiquement acceptable de celui-ci, un ester de celui-ci, un isomère de celui-ci, un marqueur isotopique de celui-ci, et l'utilisation de celui-ci dans le traitement de maladies associées à médiation par TYK2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280014108.9A CN116888125B (zh) | 2021-04-07 | 2022-04-06 | Tyk2抑制剂及其用途 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110371264 | 2021-04-07 | ||
CN202110371264.8 | 2021-04-07 | ||
CN202110969738.9 | 2021-08-23 | ||
CN202110969738 | 2021-08-23 | ||
CN202210287380 | 2022-03-23 | ||
CN202210287380.6 | 2022-03-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022213980A1 true WO2022213980A1 (fr) | 2022-10-13 |
Family
ID=83545995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/085308 WO2022213980A1 (fr) | 2021-04-07 | 2022-04-06 | Inhibiteur de tyk2 et son utilisation |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN116888125B (fr) |
TW (1) | TWI804266B (fr) |
WO (1) | WO2022213980A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023076161A1 (fr) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Agents de dégradation de tyk2 et leurs utilisations |
WO2023109954A1 (fr) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Inhibiteurs de tyk2 et compositions et procédés associés |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020086616A1 (fr) * | 2018-10-22 | 2020-04-30 | Fronthera U.S. Pharmaceuticals Llc | Inhibiteurs de tyk2 et leurs utilisations |
CN111909140A (zh) * | 2019-04-12 | 2020-11-10 | 明慧医药(杭州)有限公司 | 作为tyk2抑制剂的杂环化合物及合成和使用方法 |
CN111936486A (zh) * | 2018-03-22 | 2020-11-13 | 百时美施贵宝公司 | 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物 |
CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2735545C2 (ru) * | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
-
2022
- 2022-04-06 TW TW111113140A patent/TWI804266B/zh active
- 2022-04-06 CN CN202280014108.9A patent/CN116888125B/zh active Active
- 2022-04-06 WO PCT/CN2022/085308 patent/WO2022213980A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111936486A (zh) * | 2018-03-22 | 2020-11-13 | 百时美施贵宝公司 | 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物 |
WO2020086616A1 (fr) * | 2018-10-22 | 2020-04-30 | Fronthera U.S. Pharmaceuticals Llc | Inhibiteurs de tyk2 et leurs utilisations |
CN111909140A (zh) * | 2019-04-12 | 2020-11-10 | 明慧医药(杭州)有限公司 | 作为tyk2抑制剂的杂环化合物及合成和使用方法 |
CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023076161A1 (fr) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Agents de dégradation de tyk2 et leurs utilisations |
WO2023109954A1 (fr) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Inhibiteurs de tyk2 et compositions et procédés associés |
Also Published As
Publication number | Publication date |
---|---|
TWI804266B (zh) | 2023-06-01 |
CN116888125A (zh) | 2023-10-13 |
CN116888125B (zh) | 2024-04-12 |
TW202239758A (zh) | 2022-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023162216A (ja) | Pd-l1免疫調節剤としてのテトラヒドロ-イミダゾ[4,5-c]ピリジン誘導体 | |
KR101530117B1 (ko) | 야누스 키나제 억제제 화합물 및 방법 | |
US11597721B2 (en) | Heterocyclic compounds comprising pyridine useful as modulators of IL-12, IL-23 and/or IFNα responses | |
AU2020446002A1 (en) | Benzothiazolyl biaryl compound, and preparation method and use | |
TW202144345A (zh) | Kras突變蛋白抑制劑 | |
TWI823959B (zh) | 吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用 | |
CN102131390A (zh) | ***并吡啶jak抑制剂化合物和方法 | |
KR20060111716A (ko) | 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온 | |
WO2022213980A1 (fr) | Inhibiteur de tyk2 et son utilisation | |
TWI781607B (zh) | 一種免疫抑制劑、其製備方法和應用 | |
JP2019507766A (ja) | 線維症の治療のための新規化合物及びその医薬組成物 | |
WO2018019222A1 (fr) | Composé hétérocyclique en tant qu'inhibiteur de jak, ses sels et leur utilisation thérapeutique | |
KR20170129192A (ko) | Tnf의 억제제로서 유용한 헤테로시클릭 화합물 | |
JP2023539136A (ja) | Tlr9阻害剤として有用な置換ヘテロアリール化合物 | |
JP2023538091A (ja) | Btk阻害剤としての複素環式化合物 | |
CN116102535A (zh) | 一种含氮化合物、其制备方法及应用 | |
CN115197208A (zh) | 杂芳基类化合物、其制备方法及其在医药上的应用 | |
WO2022089389A1 (fr) | Composé hétérocyclique, procédé de préparation s'y rapportant, composition pharmaceutique associée et application associée | |
CN113773262A (zh) | 哒嗪类化合物 | |
WO2022253311A1 (fr) | Inhibiteur de hpk1 et son utilisation | |
WO2022117090A1 (fr) | Composé polycyclique, son procédé de préparation et son utilisation | |
JP2024516194A (ja) | Pd1/pd-l1阻害剤としての化合物及びその方法 | |
WO2022111636A1 (fr) | Composé tryciclique fusionné, son procédé de préparation et son utilisation en médecine | |
JP2023533003A (ja) | ヘテロ環式免疫調節物質 | |
CN114605390A (zh) | 具有cdk激酶抑制活性的化合物、其药物组合物和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22784046 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280014108.9 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22784046 Country of ref document: EP Kind code of ref document: A1 |